0001493152-16-009470.txt : 20160506 0001493152-16-009470.hdr.sgml : 20160506 20160506090309 ACCESSION NUMBER: 0001493152-16-009470 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160506 DATE AS OF CHANGE: 20160506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LIXTE BIOTECHNOLOGY HOLDINGS, INC. CENTRAL INDEX KEY: 0001335105 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202903526 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-51476 FILM NUMBER: 161626051 BUSINESS ADDRESS: STREET 1: 248 ROUTE 25A STREET 2: NO. 2 CITY: EAST SETAUKET STATE: NY ZIP: 11733 BUSINESS PHONE: 310 203 2902 MAIL ADDRESS: STREET 1: 248 ROUTE 25A STREET 2: NO. 2 CITY: EAST SETAUKET STATE: NY ZIP: 11733 FORMER COMPANY: FORMER CONFORMED NAME: SRKP 7 INC DATE OF NAME CHANGE: 20050803 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2016

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 000-51476

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware		20-2903526
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification Number)

248 Route 25A, No. 2

East Setauket, New York 11733

(Address of principal executive offices)

(631) 942-7959

(Registrant’s telephone number, including area code)

Not applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Large accelerated filer [ ]	Accelerated filer [ ]
Non-accelerated filer [ ]	Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

As of April 29, 2016, the Company had 47,875,814 shares of common stock, $0.0001 par value, issued and outstanding.

Documents incorporated by reference: None

LIXTE BIOTECHNOLOGY HOLDINGS, INC.
AND SUBSIDIARY

TABLE OF CONTENTS

	Page Number

PART I - FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements	F-1

Condensed Consolidated Balance Sheets - March 31, 2016 (Unaudited) and December 31, 2015	F-1

Condensed Consolidated Statements of Operations (Unaudited) - Three Months Ended March 31, 2016 and 2015	F-2

Condensed Consolidated Statement of Stockholders’ Equity (Unaudited) - Three Months Ended March 31, 2016	F-3

Condensed Consolidated Statements of Cash Flows (Unaudited) - Three Months Ended March 31, 2016 and 2015	F-4

Notes to Condensed Consolidated Financial Statements (Unaudited) - Three Months Ended March 31, 2016 and 2015	F-5

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	4

Item 3. Quantitative and Qualitative Disclosures About Market Risk	14

Item 4. Controls and Procedures	14

PART II - OTHER INFORMATION

Item 1. Legal Proceedings	15

Item 1A. Risk Factors	15

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	15

Item 3. Defaults Upon Senior Securities	15

Item 4. Mine Safety Disclosures	15

Item 5. Other Information	15

Item 6. Exhibits	15

SIGNATURES	16

Forward-Looking Statements

This Quarterly Report on Form 10-Q of Lixte Biotechnology Holdings, Inc. (the “Company”) contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These might include statements regarding the Company’s financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as “intend,” “anticipate,” “believe,” “estimate,” “potential(ly),” “continue,” “forecast,” “predict,” “plan,” “may,” “will,” “could,” “would,” “should,” “expect” or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. These forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected, anticipated or implied in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies or changes thereto, available cash, research and development results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included in Item 1 of this Quarterly Report on Form 10-Q and the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015, including the section entitled “Item 1A. Risk Factors”. The Company does not intend to update or revise any forward-looking statements to reflect new information, future events or otherwise.

PART I - FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31, 2016			December 31, 2015
	(Unaudited)

ASSETS
Current assets:
Cash	$	99,386		$	25,281
Money market funds		870,773			104,095
License fee receivable		—			200,000
Advances on research and development contract services, including $183,063 and $185,392 made to or through Theradex at March 31, 2016 and December 31, 2015, respectively		200,398			207,677
Prepaid expenses and other current assets		54,146			60,922
Total current assets		1,224,703			597,975
Total assets	$	1,224,703		$	597,975

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	83,403		$	159,076
Research and development contract liabilities, including $47,854 and $88,162 to Theradex at March 31, 2016 and December 31, 2015, respectively		107,212			124,566
Dividend payable on Series A Convertible Preferred Stock		2,000			2,000
Total current liabilities		192,615			285,642

Commitments and contingencies

Stockholders’ equity:
Series A Convertible Preferred Stock, $0.0001 par value, $10.00 per share stated value, $50.00 per share redemption value; 350,000 shares and 175,000 shares authorized, issued and outstanding at March 31, 2016 and December 31, 2015, respectively; aggregate redemption values of $17,500,000 and $8,750,000 at March 31, 2016 and December 31, 2015, respectively; liquidation preference based on assumed conversion into common shares; 4,375,000 shares and 2,187,500 shares of common stock issuable upon conversion at March 31, 2016 and December 31, 2015, respectively		3,500,000			1,750,000
Common stock, $0.0001 par value; authorized – 100,000,000 shares; issued and outstanding – 47,875,814 shares at March 31, 2016 and December 31, 2015		4,787			4,787
Additional paid-in capital		17,099,445			17,129,815
Subscription receivable for Series A Convertible Preferred Stock		(583,332	)		—
Accumulated deficit		(18,988,812	)		(18,572,269	)
Total stockholders’ equity		1,032,088			312,333
Total liabilities and stockholders’ equity	$	1,224,703		$	597,975

See accompanying notes to condensed consolidated financial statements (unaudited).

F-1

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended March 31,
	2016			2015

Licensing revenues	$	—		$	—

Costs and expenses:
General and administrative costs, including $6,250 and $81,151 to related parties for the three months ended March 31, 2016 and 2015, respectively		152,057			246,643
Research and development costs, including $116,633 and $353,037 to Theradex for the three months ended March 31, 2016 and 2015, respectively		264,497			505,514
Total costs and expenses		416,554			752,157
Loss from operations		(416,554	)		(752,157	)
Interest income		11			11
Fair value of warrant extensions		—			(34,016	)
Fair value of warrant discount		—			(171,757	)
Net loss		(416,543	)		(957,919	)
Dividend on Series A Convertible Preferred Stock		—			—
Net loss attributable to common stockholders	$	(416,543	)	$	(957,919	)

Net loss per common share – basic and diluted	$	(0.01	)	$	(0.02	)

Weighted average common shares outstanding – basic and diluted		47,875,814			45,498,550

See accompanying notes to condensed consolidated financial statements (unaudited).

F-2

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

(Unaudited)

Three Months Ended March 31, 2016

	Series A											Series A
	Convertible											Convertible
	Preferred Stock				Common Stock				Additional			Preferred Stock						Total
							Par		Paid-in			Subscription			Accumulated			Stockholders’
	Shares		Amount		Shares		Value		Capital			Receivable			Deficit			Equity

Balance, December 31, 2015		175,000	$	1,750,000		47,875,814	$	4,787	$	17,129,815		$	—		$	(18,572,269	)	$	312,333
Sale of Series A Convertible Preferred Stock under stock subscription		175,000		1,750,000		—		—		—			(1,750,000	)		—			—
Subscription payments received from sale of Series A Convertible Preferred Stock		—		—		—		—		—			1,166,668			—			1,166,668
Stock-based compensation expense (credit)		—		—		—		—		(30,370	)		—			—			(30,370	)
Net loss		—		—		—		—		—			—			(416,543	)		(416,543	)
Balance, March 31, 2016		350,000	$	3,500,000		47,875,814	$	4,787	$	17,099,445		$	(583,332	)	$	(18,988,812	)	$	1,032,088

See accompanying notes to condensed consolidated financial statements (unaudited).

F-3

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three Months Ended March 31,
	2016			2015

Cash flows from operating activities:
Net loss	$	(416,543	)	$	(957,919	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense (credit) included in -
General and administrative costs		—			81,678
Research and development costs		(30,370	)		2,316
Fair value of warrant -
Extensions		—			34,016
Discounts		—			171,757
Changes in operating assets and liabilities:
(Increase) decrease in -
Licensing fee receivable		200,000			—
Advances on research and development contract services		7,279			55,654
Prepaid expenses and other current assets		6,776			401
Increase (decrease) in -
Accounts payable and accrued expenses		(75,673	)		(12,575	)
Research and development contract liabilities		(17,354	)		86,038
Net cash used in operating activities		(325,885	)		(538,634	)

Cash flows from investing activities:
(Increase) decrease in money market funds		(766,678	)		(1,103,068	)
Net cash used in investing activities		(766,678	)		(1,103,068	)

Cash flows from financing activities:
Proceeds from sale of Series A Convertible Preferred Stock		—			1,750,000
Cash payments made for costs incurred in connection with sale of Series A Convertible Preferred Stock		—			(12,608	)
Cash received from sale of Series A Convertible Preferred Stock		1,166,668			—
Net cash provided by financing activities		1,166,668			1,737,392

Cash:
Net increase		74,105			95,690
Balance at beginning of period		25,281			44,411
Balance at end of period	$	99,386		$	140,101

Supplemental disclosures of cash flow information:
Cash paid for -
Interest	$	—		$	—
Income taxes	$	—		$	—

Non-cash financing activities:
Conversion of advances due to Chairman and major stockholder into common stock	$	—		$	92,717
Sale of Series A Convertible Preferred Stock under stock subscription	$	1,750,000		$	—

See accompanying notes to condensed consolidated financial statements (unaudited).

F-4

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Three Months Ended March 31, 2016 and 2015

1. Organization, Business and Basis of Presentation

Organization and Business

Lixte Biotechnology Holdings, Inc., a Delaware corporation (“Holdings”), including its wholly-owned Delaware subsidiary, Lixte Biotechnology, Inc. (“Lixte”) (collectively, the “Company”), is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Company’s product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases.

The Company’s activities are subject to significant risks and uncertainties, including the need for additional capital, as described below. The Company has not yet commenced any sustainable revenue-generating operations, does not have any positive cash flows from operations, and is dependent on equity capital to fund its operating requirements.

The Company’s common stock is traded on the OTCQB operated by the OTC Markets under the symbol “LIXT”.

Basis of Presentation

The condensed consolidated financial statements of the Company at March 31, 2016, and for the three months ended March 31, 2016 and 2015, are unaudited. In the opinion of management of the Company, all adjustments (including normal recurring adjustments) have been made that are necessary to present fairly the financial position of the Company as of March 31, 2016, and the results of its operations for the three months ended March 31, 2016 and 2015, and its cash flows for the three months ended March 31, 2016 and 2015. Operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal year. The consolidated balance sheet at December 31, 2015 has been derived from the Company’s audited financial statements at such date.

The statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the financial statements and other information included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015, as filed with the SEC.

Going Concern

The Company’s condensed consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any sustainable revenues from operations to date, and does not expect to do so in the foreseeable future. The Company has experienced recurring operating losses and negative operating cash flows since inception, and has financed its working capital requirements during this period primarily through the recurring sale of its equity securities and the exercise of outstanding warrants. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern, and the Company’s independent registered public accounting firm, in their report on the Company’s consolidated financial statements for the year ended December 31, 2015, has expressed substantial doubt about the Company’s ability to continue as a going concern.

F-5

The Company’s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research and development activities and to ultimately achieve sustainable operating revenues and profits. The Company’s consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

Because the Company is currently engaged in research at a relatively early stage, it will likely take a significant amount of time to develop any product or intellectual property capable of generating sustainable revenues. Accordingly, the Company’s business is unlikely to generate any sustainable operating revenues in the next several years, and may never do so. In addition, to the extent that the Company is able to generate revenues through licensing its technologies or through product sales, there can be no assurance that the Company will be able to achieve positive earnings and operating cash flows.

At March 31, 2016, the Company had cash and money market funds aggregating $970,159. In January 2016, the Company entered into an agreement to sell additional shares of preferred stock for aggregate cash proceeds of $1,750,000 to be received by June 3, 2016, in three approximately equal installments. As of March 31, 2016, the Company had received two such installments totaling $1,166,668, with the third installment scheduled to be received by June 3, 2016. The Company also expects to receive a refund of an advance made through Theradex of $181,510 upon the completion of the current clinical trial. Consequently, the Company believes that it will have sufficient funds to complete the Phase 1 clinical trial of its lead anti-cancer compound LB-100 and to conduct a Phase 1b/2 clinical trial of LB-100 in the hematologic disorder known as myelodysplastic syndrome, as well as to fund the Company’s ongoing operating expenses, including maintaining its patent portfolio, through mid-2017.

The amount and timing of future cash requirements will depend on the pace and design of the Company’s clinical trial program. The Company currently plans to attempt to raise an additional approximately $3,000,000 of capital in the second half of 2016, likely in the form of equity, to also conduct a Phase 1b/2 clinical trial of LB-100 in combination with a platinum compound in platinum-resistant ovarian cancer and to extend the Company’s pre-clinical research on compounds in its pipeline.

As market conditions present uncertainty as to the Company’s ability to secure additional funds, there can be no assurances that the Company will be able to secure additional financing on acceptable terms, or at all, as and when necessary to continue to conduct operations. If cash resources are insufficient to satisfy the Company’s ongoing cash requirements, the Company would be required to scale back or discontinue its technology and product development programs and/or clinical trials, or obtain funds, if available (although there can be no certainty), through strategic alliances that may require the Company to relinquish rights to certain of its compounds, or to discontinue its operations entirely.

2. Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying condensed consolidated financial statements of the Company are prepared in accordance with United States generally accepted accounting principles (“GAAP”) and include the financial statements of Holdings and its wholly-owned subsidiary, Lixte. Intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Cash Concentrations

The Company’s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date. The Company maintains its accounts with financial institutions with high credit ratings.

F-6

Research and Development

Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s treatments and product candidates.

Research and development costs are expensed ratably over the life of the underlying contracts, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. The costs of the Phase 1 clinical trial of LB-100 that are being paid through Theradex, the CRO, are recorded and expensed based upon the documentation provided by the CRO.

Payments made pursuant to research and development contracts are initially recorded as advances on research and development contract services in the Company’s balance sheet and then charged to research and development costs in the Company’s statement of operations as those contract services are performed. Expenses incurred under research and development contracts in excess of amounts advanced are recorded as research and development contract liabilities in the Company’s balance sheet, with a corresponding charge to research and development costs in the Company’s statement of operations. The Company reviews the status of its research and development contracts on a quarterly basis.

At March 31, 2016, the Company had advances made to or through Theradex aggregating $183,063, of which $181,510 is expected to be refunded to the Company upon completion of the Company’s Phase 1 clinical trial of LB-100.

Patent Costs

Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred. Patent costs were $101,956 and $127,481 for the three months ended March 31, 2016 and 2015, respectively. Patent costs are included in research and development costs in the Company’s condensed consolidated statements of operations.

Accounting for Preferred Stock

The Company accounts for preferred stock as either equity or debt, depending on the specific characteristics of the security issued. The Series A Convertible Preferred Stock issued by the Company in January 2016 and March 2015 has been classified in stockholders’ equity, as described at Note 4.

Concentration of Risk

The Company periodically contracts with directors, including companies controlled by or associated with directors, to provide consulting services related to the Company’s research and development and clinical trial activities. Agreements for these services can be for a specific time period (typically one year) or for a specific project or task, and can include both cash and non-cash compensation. The only such contract that represents 10% or more of general and administrative or research and development costs is described below.

The Phase 1 clinical trial is currently estimated to cost a total of approximately $2,200,000, with such payments expected to be allocated approximately 60% for services provided by Theradex and approximately 40% for pass-through costs for clinical center laboratory costs and investigator costs over the life of the clinical trial. Total costs charged to operations through March 31, 2016 for services paid to or through Theradex pursuant to this arrangement, which were first incurred in 2013, aggregated $1,774,276, of which $113,551 and $350,601 were incurred during the three months ended March 31, 2016 and 2015, respectively, or approximately 43% and 69% of research and development costs for the three months ended March 31, 2016 and 2015, respectively. Costs pursuant to this agreement are included in research and development costs in the Company’s condensed consolidated statements of operations.

F-7

Income Taxes

The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities.

The Company has elected to deduct research and development costs on a current basis for federal income tax purposes. For federal tax purposes, start-up and organization costs were deferred until January 1, 2008 at which time the Company began to amortize such costs over a 180-month period.

The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made.

The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of March 31, 2016 and 2015 and does not anticipate any material amount of unrecognized tax benefits within the next 12 months.

The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of March 31, 2016, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense.

Stock-Based Compensation

The Company periodically issues common stock and stock options to officers, directors, Scientific Advisory Committee members and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each grant.

The Company accounts for stock-based payments to officers and directors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s financial statements over the vesting period of the awards. The Company accounts for stock-based payments to Scientific Advisory Committee members and consultants by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached or (b) at the date at which the necessary performance to earn the equity instruments is complete.

Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.

Stock options granted to members of the Company’s Scientific Advisory Committee and to outside consultants are revalued each reporting period to determine the amount to be recorded as an expense in the respective period. As the stock options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the value on the date of vesting.

The fair value of common stock issued as stock-based compensation is determined by reference to the closing price of the Company’s common stock on the date of issuance. The fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award. Estimated volatility is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market value of common stock is determined by reference to the quoted market price of the Company’s common stock.

F-8

The Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development costs, as appropriate, in the Company’s condensed consolidated statement of operations. The Company issues new shares of common stock to satisfy stock option exercises.

Revenue Recognition

The Company recognizes revenue when all four of the following criteria are met: (i) persuasive evidence that an arrangement exists; (ii) delivery of the products and/or services has occurred; (iii) the fees earned can be readily determined; and (iv) collectability of the fees is reasonably assured.

Revenues from milestone payments under license agreements are recognized when earned and the Company has no further performance obligations thereunder.

Comprehensive Income (Loss)

Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). The Company did not have any items of comprehensive income (loss) for the three months ended March 31, 2016 and 2015.

Earnings (Loss) Per Share

The Company’s computation of earnings (loss) per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares, warrants and stock options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.

Net income (loss) attributable to common stockholders consists of net income or loss, as adjusted for preferred stock dividends declared, amortized or accumulated.

Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all preferred shares, warrants and stock options outstanding are anti-dilutive.

At March 31, 2016 and 2015, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.

	March 31,
	2016		2015

Series A Convertible Preferred Stock		4,375,000		2,187,500
Common stock warrants		—		2,928,800
Common stock options		7,950,000		6,825,000
Total		12,325,000		11,941,300

Fair Value of Financial Instruments

The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required.

F-9

Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives.

Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges.

Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models.

The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end.

Money market funds are the only financial instrument that is measured and recorded at fair value on the Company’s consolidated balance sheet on a recurring basis.

The carrying value of financial instruments (consisting of cash and accounts payable and accrued expenses) is considered to be representative of their respective fair values due to the short-term nature of those instruments.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. Based on the FASB’s Exposure Draft Update issued on April 29, 2015, Revenue from Contracts With Customers (Topic 606): Deferral of the Effective Date, it is expected that ASU 2014-09 will now be effective for reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The adoption of ASU 2014-09 is not expected to have any impact on the Company’s financial statement presentation or disclosures.

In August 2014, the FASB issued Accounting Standards Update No. 2014-15 (ASU 2014-15), Presentation of Financial Statements – Going Concern (Subtopic 205-10). ASU 2014-15 provides guidance as to management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. In connection with preparing financial statements for each annual and interim reporting period, an entity’s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued (or at the date that the financial statements are available to be issued when applicable). Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have any impact on the Company’s financial statement presentation and disclosures.

F-10

In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The Company has not yet evaluated the impact of the adoption of ASU 2016-02 on the Company’s financial statement presentation or disclosures.

Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

3. License Agreement

Effective December 25, 2015, the Company entered into a License Agreement (the “TMU License Agreement”) with Taipei Medical University (“TMU”), pursuant to which the Company granted to TMU an exclusive license of its lead anti-cancer compound, LB-100, for treatment of hepatocellular carcinoma (“HCC”) in Asia. Under the TMU License Agreement, TMU will determine the effectiveness of LB-100 against HCC in clinical trials conducted in accordance with both Taiwan and United States regulatory requirements.

Under the TMU License Agreement, TMU is obligated to make non-refundable milestone payments to the Company of $200,000 within ninety days from the effective date of December 25, 2015, $50,000 upon the completion of the first Phase 1b/2 clinical trial, $150,000 upon the completion of the first Phase 3 clinical trial, and $200,000 upon the first filing of a New Drug Application (“NDA”) with the FDA or a comparable non-United States regulatory authority. During the term of the TMU License Agreement, TMU will also pay earned royalties of 10% on cumulative net sales, and 10% to 15% on non-sale based sub-license income. A Phase 1b/2 clinical trial of LB-100 plus doxorubicin, to be managed and funded by TMU, is expected to commence during the third quarter of 2016.

The Company did not have any further performance obligations under the TMU License Agreement on the December 25, 2015 effective date. Accordingly, as the $200,000 licensing fee was fully earned on the December 25, 2015 effective date, the Company recorded such amount as licensing fee revenue at December 31, 2015. The Company received the $200,000 milestone payment on March 18, 2016.

4. Stockholders’ Equity

Preferred Stock

The Company has authorized a total of 10,000,000 shares of preferred stock, par value $0.001 per share. On March 17, 2015, the Company filed a Certificate of Designations, Preferences, Rights and Limitations (the “Certificate of Designations”) of its Series A Convertible Preferred Stock with the Delaware Secretary of State to amend the Company’s certificate of incorporation. The number of shares designated as Series A Convertible Preferred Stock was 175,000 (which are not subject to increase without the written consent of a majority of the holders of the Series A Convertible Preferred Stock or as otherwise set forth in the Certificate of Designations). Effective January 28, 2016, the Series A Convertible Preferred Stock Certificate of Designations was amended to increase the number of authorized shares of Series A Convertible Preferred Stock from 175,000 to 350,000. Accordingly, as of March 31, 2016, 9,650,000 shares of preferred stock were undesignated and may be issued with such rights and powers as the Board of Directors may designate

Effective March 17, 2015, the Company entered into a Securities Purchase Agreement with a current stockholder of the Company who owned 10.6% of the Company’s issued and outstanding shares of common stock immediately prior to the financing transaction, pursuant to which such stockholder purchased 175,000 shares of the Company’s non-voting Series A Convertible Preferred Stock (the “Preferred Stock”) at a price per share of $10.00, representing an aggregate purchase price of $1,750,000.

F-11

Effective January 28, 2016, the Company entered into a Securities Purchase Agreement with the holder of the Preferred Stock sold on March 17, 2015, pursuant to which the Company sold an additional 175,000 shares of Preferred Stock at a price per share of $10.00, representing an aggregate purchase price of $1,750,000, payable $583,333 on closing, $583,333 on or before March 4, 2016, and $583,334 on or before June 3, 2016. The first two installments were received during the three months ended March 31, 2016.

This class of Preferred Stock has a dividend per share equal to 1% of the annual net revenue of the Company divided by 175,000, until converted or redeemed. Based on the Company’s net revenues for the year ended December 31, 2015 of $200,000, the Company recorded a dividend of $2,000 on the shares of Preferred Stock issued and outstanding at that time. The dividend has been presented as a current liability in the Company’s condensed consolidated balance sheets as of March 31, 2016 and December 31, 2015.

Each share of Preferred Stock may be converted, at the option of the holder, into 12.5 shares of common stock (subject to customary anti-dilution provisions) and the Preferred Stock is subject to mandatory conversion at the conversion rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $21,875,000. The Preferred Stock has a liquidation preference based on its assumed conversion into shares of common stock.

If fully converted, the Preferred Stock sold in the March 17, 2015 closing would convert into 2,187,500 shares of common stock, representing an effective price per share of common stock of $0.80. On March 17, 2015, the closing price of the Company’s common stock was $0.25 per share. If fully converted, the Preferred Stock sold in the January 21, 2016 closing would also convert into 2,187,500 shares of common stock, representing an effective price per share of common stock of $0.80. On January 21, 2016, the closing price of the Company’s common stock was $0.22 per share. The Company has the right to redeem the Preferred Stock up to the fifth anniversary of the respective closing dates at a price per share equal to $50.00. The Preferred Stock has no right to cash, except for the payment of the aforementioned dividend when the Company generates revenues, and does not have any registration rights.

Based on the attributes of the Preferred Stock described above, the Company has determined to account for the Preferred Stock as a permanent component of stockholders’ equity. Legal costs of $12,608 incurred with respect to the issuance of the Preferred Stock on March 17, 2015 were charged directly to additional paid-in capital. No costs were incurred with respect to the issuance of the Preferred Stock on January 21, 2016.

Common Stock

Effective March 17, 2015, the Company’s Chairman and major stockholder converted advances due to him aggregating $92,717 into 92,717 shares of the Company’s common stock, reflecting an effective price of $1.00 per share. On the effective date of the transaction, the closing price of the Company’s common stock was $0.25 per share. The Company accounted for this transaction as a capital transaction.

See Note 7 for information with respect to the issuance of common stock in connection with various stock-based compensation arrangements.

Common Stock Warrants

On March 6, 2015, the Company’s Board of Directors extended to April 15, 2015 the outstanding warrants to acquire 2,928,800 shares of the Company’s common stock, which were then currently scheduled to expire on March 31, 2015, and discounted the cash exercise prices of the warrants by 50%. Warrants so extended and discounted consisted of 1,075,000 warrants currently exercisable at $0.75 per share and 1,853,800 warrants currently exercisable at $0.50 per share. The difference in the fair value of the warrants immediately before and after the grant of the extensions, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $34,016 (average of $0.01 per share), and such amount was charged to operations on March 6, 2015. The fair value of the warrant extensions was calculated using the following input variables: stock price - $0.30 per share; exercise price - $0.50 and $0.75 per share; expected life – 25 to 40 days; expected volatility – 199%; expected dividend yield - 0%; risk-free interest rate – 0.01%. The difference in the fair value of the warrants immediately before and after the grant of the discount, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $171,757 (an average of $0.06 per share), and such amount was charged to operations on March 6, 2015. The fair value of the warrant discount was calculated using the following input variables: stock price - $0.30 per share; exercise price - $0.50 and $0.75 per share to $0.25 and $0.375 per share, respectively; expected life – 15 days (the period during which the discount was available); expected volatility – 199%; expected dividend yield - 0%; risk-free interest rate – 0.01%.

F-12

As a result of the March 6, 2015 warrant extension and discount offers, warrants to acquire 1,050,000 shares of the Company’s common stock were exercised in April 2015 (including warrants to acquire 500,000 shares of common stock by Dr. Debbie Schwartzberg, an affiliate of the Company, and 300,000 shares of common stock by Philip F. Palmedo, a director of the Company) at exercise prices ranging from $0.25 to $0.375 per share. The exercise of the warrants generated aggregate net proceeds to the Company of $315,000 (average exercise price of $0.30 per share).

As of December 31, 2015 and March 31, 2016, there were no warrants outstanding to purchase common stock.

5. Money Market Funds

Money market funds at March 31, 2016 and December 31, 2015 consisted of investments in shares of Morgan Stanley New York Municipal Money Market Trust with a market value of $870,773 and $104,095, respectively.

The Morgan Stanley New York Municipal Money Market Trust is an open-end fund incorporated in the USA. The Fund’s objective is as high level of daily income exempt from federal and New York income tax as is consistent with stability of principal and liquidity. The Fund invests in high quality, short- term municipal obligations that pay interest exempt from federal and NY taxes.

The following table presents money market funds at their level within the fair value hierarchy at March 31, 2016 and December 31, 2015.

	Total		Level 1		Level 2		Level 3

March 31, 2016:
Money market funds	$	870,773	$	870,773	$	—	$	—

December 31, 2015:
Money market funds	$	104,095	$	104,095	$	—	$	—

6. Related Party Transactions

The Company had advances from its Chairman and major stockholder, Dr. John Kovach, aggregating $92,717, which were non-interest bearing, due on demand, and included in current liabilities in the Company’s consolidated balance sheets through December 31, 2014. Effective March 17, 2015, such advances were converted into 92,717 shares of the Company’s common stock, reflecting an effective price of $1.00 per share. On the effective date of the transaction, the closing price of the Company’s common stock was $0.25 per share.

Dr. Kovach was paid a salary of $15,000 for the three months ended March 31, 2016 and 2015, which amounts are included in general and administrative costs in the Company’s condensed consolidated statements of operations.

Dr. Kovach is not involved in other business activities but could, in the future, become involved in other business opportunities that become available. Accordingly, Dr. Kovach may face a conflict in selecting between the Company and his other business interests. The Company has not yet formulated a policy for the resolution of such potential conflicts.

The Company’s principal office facilities have been provided without charge by Dr. Kovach. Such costs were not material to the Company’s consolidated financial statements and, accordingly, have not been reflected therein.

Legal and consulting fees charged to operations for services rendered by the Eric Forman Law Office were $12,000 for the three months ended March 31, 2016 and 2015. Eric J. Forman is the son-in-law of Gil Schwartzberg, a significant stockholder of and consultant to the Company.

F-13

Effective January 1, 2014, the Company entered into an Advisory Agreement with Dr. Kathleen P. Mullinix, a member of the Board of Directors of the Company, effective for an initial term of one year through December 31, 2014 to advise on business development matters. The Advisory Agreement provided for annual cash compensation of $25,000. The term of the Advisory Agreement is automatically extended for a term of one year annually unless a notice of intent to terminate is given by either party at least 90 days before the end of the applicable term. Accordingly, the Advisory Agreement was extended for additional terms of one year effective January 1, 2015 and 2016. The Company recognized a charge to operations of $6,250 as consulting and advisory fees pursuant to this Advisory Agreement during the three months ended March 31, 2016 and 2015, which were included in general and administrative costs in the Company’s condensed consolidated statements of operations.

Stock-based compensation arrangements involving members of the Company’s Board of Directors and affiliates are described at Note 7. Total stock-based compensation expense relating to directors, officers, affiliates and related parties was $0 and $74,901 for the three months ended March 31, 2016 and 2015, respectively.

7. Stock-Based Compensation

The Company issues common stock and stock options as incentive compensation to directors and as compensation for the services of independent contractors and consultants of the Company.

On June 20, 2007, the Board of Directors of the Company approved the 2007 Stock Compensation Plan (the “2007 Plan”), which provides for the granting of awards, consisting of stock options, stock appreciation rights, performance shares, or restricted shares of common stock, to employees and independent contractors, for up to 2,500,000 shares of the Company’s common stock, under terms and condition, as determined by the Company’s Board of Directors. As of March 31, 2016, unexpired stock options for 550,000 shares were issued and outstanding under the 2007 Plan, and stock options for 1,950,000 were available for issuance under the 2007 Plan.

The fair value of each stock option awarded is estimated on the date of grant and subsequent measurement dates using the Black-Scholes option-pricing model. The expected dividend yield assumption is based on the Company’s expectation of dividend payouts. The expected volatilities are based on historical volatility of the Company’s stock. The risk-free interest rate is based on the U.S. treasury yield curve in effect as of the grant date. The expected life of the stock options is the average of the vesting term and the full contractual term of the stock options.

For stock options requiring an assessment of value during the three months ended March 31, 2016, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate	0.74% to 1.23	%
Expected dividend yield	0	%
Expected volatility	196.75	%
Expected life	2.7 to 4.7 years

For stock options requiring an assessment of value during the three months ended March 31, 2015, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate	1.33	%
Expected dividend yield	0	%
Expected volatility	243	%
Expected life	3.7 to 4.5 years

On January 28, 2014, the Company approved a second amendment to the Company’s consulting agreement with Gil Schwartzberg, a significant stockholder of and consultant to the Company, dated September 12, 2007 to extend it for an additional four years to January 28, 2019 and granted to Mr. Schwartzberg stock options to purchase an additional aggregate of 4,000,000 shares of common stock, exercisable for a period of the earlier of five years from the grant date or the termination of the consulting agreement at $0.50 per share, with one-half of the stock options (2,000,000 shares) vesting immediately and one-half of the stock options (2,000,000 shares) vesting on January 28, 2015. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $596,400 ($0.15 per share) on January 28, 2014, of which $298,200 was attributed to the stock options that were fully vested on January 28, 2014 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from January 28, 2014 through January 28, 2015. During the three months ended March 31, 2015, the Company recorded a charge to operations of $74,901 with respect to these stock options.

F-14

On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. (“NDA”) for consultation and advice in the field of oncology research and drug development. As part of the agreement, NDA also agreed to cause its president, Dr. Daniel D. Von Hoff, M.D., to become a member of the Company’s Scientific Advisory Committee. In connection with this agreement, NDA was granted stock options to purchase 100,000 shares of the Company’s common stock, vesting 25,000 shares on June 24, 2014, and thereafter 25,000 shares annually on June 24, 2015, 2016 and 2017, exercisable for a period of five years from the date of grant at $0.13 per share, which was the fair market value of the Company’s common stock on the grant date. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $12,960 ($0.13 per share), and is being charged to operations ratably from December 24, 2013 through June 24,2017. During the three months ended March 31, 2016 and 2015, the Company recorded a (credit) charge to operations of $(10,796) and $2,316, respectively, with respect to these stock options.

On October 7, 2014, the Company entered into an Advisory Agreement with Andrew Robell for consultation and advice with respect to identifying and assessing potential licensing and strategic opportunities through September 30, 2016. In connection with the agreement, the Company granted stock options to Mr. Robell to purchase 200,000 shares of the Company’s common stock, vesting 100,000 shares on October 7, 2014 and 100,000 shares on October 7, 2015, exercisable for a period of five years from the date of grant at $0.50 per share. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $20,000 ($0.10 per share), of which $10,000 is attributed to the stock options fully-vested on October 7, 2014 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from October 7, 2014 through October 7, 2015. During the three months ended March 31, 2015, the Company recorded a charge to operations of $6,777 with respect to these stock options.

On October 7, 2014, the Company entered into an agreement with ProActive Capital Resources Group LLC (“ProActive”) for strategic advisory, investor relations and public relations services through October 6, 2015. In connection with the agreement, the Company agreed to pay ProActive a monthly fee of $1,500 in cash and agreed to issue to ProActive 250,000 shares of the Company’s common stock, vesting 125,000 shares upon execution of the agreement on October 7, 2014 and 125,000 shares six months thereafter on April 7, 2015. Additionally, the Company issued a stock option in the form of a warrant to ProActive to purchase 500,000 shares of the Company’s common stock, vesting upon execution of the agreement on October 7, 2014, and exercisable for a period of one year from the date of grant at $0.25 per share. The fair value of the warrant, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $33,000 ($0.066 per share). The Company inadvertently neglected to timely record a charge to operations in 2014 of $45,500 with respect to this transaction, as well as to record a portion of the fair value of the remaining unvested 125,000 shares in 2014 (which had a fair value on the grant date of $12,500). The Company recorded a charge to operations for the aggregate fair value of these securities of $76,750 during the three months ended June 30, 2015. Management performed an evaluation with respect to this matter and determined that this correction was not qualitatively or quantitatively material to the Company’s financial statements for the years ended December 31, 2014 or 2015, and thus determined that no restatement of such prior periods was necessary or appropriate under the circumstances.

Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks LLC (“BioPharmaWorks”), pursuant to which the Company engaged BioPharmaWorks to perform certain services for the Company as described at Note 8. In connection with the Collaboration Agreement, the Company agreed to issue to BioPharmaWorks 1,000,000 fully-vested shares of the Company’s common stock, valued at $260,000, based upon the closing price of the Company’s common stock of $0.26 per share, on September 14, 2015. Additionally, the Company issued to BioPharmaWorks two options in the form of warrants to purchase 1,000,000 shares (500,000 shares per warrant) of the Company’s common stock. The first warrant will vest on September 14, 2016, and is exercisable for a period of five years from the date of grant at $1.00 per share. The second warrant will vest on September 14, 2017, and is exercisable for a period of five years from the date of grant at $2.00 per share. The fair value of the first and second warrants, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $128,400 ($0.2568 per share) and $127,850 ($0.2557 per share), respectively. During the three months ended March 31, 2016, the Company recorded a credit to operations of $(20,733) with respect to these common shares and warrants.

F-15

On November 28, 2015, the Company entered into a two-year advisory agreement with Dr. Fritz Henn, M.D., Ph.D., for consultation and advice on the development of certain of the Company’s products for clinical neurological and neuropsychiatric applications. Dr. Henn is an internationally recognized investigative neuroscientist and psychiatrist. In connection with the advisory agreement, and as sole compensation, Dr. Henn was granted stock options to purchase 200,000 shares of the Company’s common stock, with 100,000 shares vesting on November 28, 2015, and 100,000 shares vesting on November 28, 2016. The stock options are exercisable for a period of five years from the grant date at $0.50 per share. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $103,360 ($0.5168 per share), of which $51,680 is attributed to the options fully-vested on November 28, 2015 and was therefore was charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from November 28, 2015 through November 28, 2016. During the three months ended March 31, 2016, the Company recorded a charge to operations of $1,159 with respect to these stock options.

Total stock-based compensation expense (credit) was $(30,370) and $83,994, respectively, for the three months ended March 31, 2016 and 2015. The credit for the vested portion of the fair value of common stock options and warrants of $(30,370) for the three months ended March 31, 2016 was primarily attributable to a decline in the Company’s stock price from December 31, 2015 through March 31, 2016.

A summary of stock option activity during the three months ended March 31, 2016 is presented in the tables below.

					Weighted
					Average
			Weighted		Remaining
	Number		Average		Contractual
	Of		Exercise		Life
	Shares		Price		(in Years)

Options outstanding at December 31, 2015		7,950,000	$	0.697
Granted		—		—
Exercised		—		—
Expired		—		—
Options outstanding at March 31, 2016		7,950,000	$	0.697		2.69

Options exercisable at December 31, 2015		6,800,000	$	0.586
Options exercisable at March 31, 2016		6,800,000	$	0.586		2.40

Total deferred compensation expense for the outstanding value of unvested stock options was approximately $74,000 at March 31, 2016, which is being recognized subsequent to March 31, 2016 over a weighted-average period of approximately twelve months.

The exercise prices of common stock options outstanding and exercisable are as follows at March 31, 2016:

		Options		Options
Exercise		Outstanding		Exercisable
Prices		(Shares)		(Shares)

$	0.130		100,000		50,000
$	0.250		500,000		500,000
$	0.500		4,400,000		4,300,000
$	0.650		700,000		700,000
$	0.980		250,000		250,000
$	1.000		1,500,000		1,000,000
$	2.000		500,000		—
			7,950,000		6,800,000

Based on a fair market value of $0.12 per share on March 31, 2016, there were no exercisable but unexercised in-the-money stock options outstanding at March 31, 2016. Such stock options had no intrinsic value at such date.

F-16

The intrinsic value of exercisable but unexercised in-the-money stock options at December 31, 2015 was approximately $31,300, based on a fair market value of $0.296 per share on December 31, 2015.

Outstanding options to acquire 1,150,000 shares of the Company’s common stock had not vested at March 31, 2016.

The Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.

8. Commitments and Contingencies

The Company is not currently subject to any pending or threatened legal actions or claims.

Significant agreements and contracts are summarized as follows:

On September 21, 2012, the Company entered into a work order agreement with Theradex, the CRO responsible for the clinical development of the Company’s lead compound, LB-100, to manage and administer the Phase 1 clinical trial of LB-100. The Phase 1 clinical trial of LB-100, which began during April 2013 with the entry of patients into the clinical trial, is being carried out by nationally recognized comprehensive cancer centers, and is estimated to be completed by May 31, 2016. The Phase 1 clinical trial is currently estimated to cost a total of approximately $2,200,000, with such payments expected to be allocated approximately 60% for services provided by Theradex and approximately 40% for pass-through costs for clinical center laboratory costs and investigator costs over the life of the clinical trial. Total costs charged to operations through March 31, 2016 for services paid to or through Theradex pursuant to this arrangement, which were first incurred in 2013, aggregated $1,774,276, of which $113,551 and $350,601 were incurred during the three months ended March 31, 2016 and 2015, respectively. Costs pursuant to this agreement are included in research and development costs in the Company’s condensed consolidated statements of operations.

Effective January 1, 2014, the Company entered into an Advisory Agreement with Dr. Kathleen P. Mullinix, a member of the Board of Directors of the Company, effective for an initial term of one year through December 31, 2014 to advise on business development matters. The Advisory Agreement provided for annual cash compensation of $25,000. The term of the Advisory Agreement was automatically extended for a term of one year annually unless a notice of intent to terminate was given by either party at least 90 days before the end of the applicable term. Accordingly, the Advisory Agreement was extended for additional terms of one year effective January 1, 2015 and 2016. The Company recognized a charge to operations of $6,250 as consulting and advisory fees pursuant to this Advisory Agreement during the three months ended March 31, 2016 and 2015.

On October 7, 2014, the Company entered into an agreement with ProActive Capital Resources Group LLC for strategic advisory, investor relations and public relations services through October 6, 2015. Among other things, the agreement provided for compensation in the form of a monthly fee of $1,500 in cash. Fees charged to operations pursuant to this agreement was $4,500 during the three months ended March 31, 2015.

Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged BioPharmaWorks to perform certain services for the Company. Those services include, among other things: (a) assisting the Company to (i) commercialize its products and strengthen its patent portfolio, (ii) identify large pharmaceutical companies with potential interest in the Company’s product pipeline, and (iii) prepare and deliver presentations concerning the Company’s products; (b) at the request of the Board of Directors, serving as backup management for up to three months should the Company’s Chief Executive Officer and scientific leader be temporarily unable to carry out his duties; (c) being available for consultation in drug discovery and development; and (d) identifying providers and overseeing tasks relating to clinical use and commercialization of new compounds. BioPharmaWorks was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience. The Collaboration Agreement is for an initial term of two years and automatically renews for subsequent annual periods unless terminated by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the Company agreed to pay BioPharmaWorks a monthly fee of $10,000, subject to the right of the Company to pay a negotiated hourly rate in lieu of the monthly payment, and agreed to issue to BioPharmaWorks certain equity-based compensation as described at Note 7. Fees charged to operations pursuant to this Collaboration Agreement was $30,000 during the three months ended March 31, 2016.

F-17

The following table sets forth the Company’s principal cash obligations and commitments for the next five fiscal years as of March 31, 2016 aggregating $494,914, of which $75,259 is included in current liabilities in the Company’s condensed consolidated balance sheet at March 31, 2016. Amounts included in the 2016 column represent amounts due at March 31, 2016 for the remainder of the 2016 fiscal year ending December 31, 2016.

			Payments Due By Year
	Total		2016		2017		2018		2019		2020

Research and development contracts	$	41,004	$	41,004	$	—	$	—	$	—	$	—
Clinical trial agreements		256,910		256,910		—		—		—		—
Consulting agreements		197,000		107,000		90,000		—		—		—
Total	$	494,914	$	404,914	$	90,000	$	—	$	—	$	—

9. Subsequent Events

The Company performed an evaluation of subsequent events through the date of filing of these financial statements with the SEC, noting no items requiring disclosure.

F-18

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

Lixte Biotechnology Holdings, Inc., a Delaware corporation, including its wholly-owned Delaware subsidiary, Lixte Biotechnology, Inc. (collectively, the “Company”), is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Company’s product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases.

The Company’s common stock is traded on the OTCQB operated by the OTC Markets under the symbol “LIXT”.

Going Concern

Recent Accounting Pronouncements

A discussion with respect to recently issued accounting standards is provided at Note 2 to the Company’s condensed consolidated financial statements.

Concentration of Risk

Critical Accounting Policies and Estimates

The Company prepared its condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Management periodically evaluates the estimates and judgments made. Management bases its estimates and judgments on historical experience and on various factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates as a result of different assumptions or conditions.

The following critical accounting policies affect the more significant judgments and estimates used in the preparation of the Company’s condensed consolidated financial statements.

Research and Development

Patent Costs

Stock-Based Compensation

Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.

The Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development costs, as appropriate, in the Company’s statement of operations. The Company issues new shares of common stock to satisfy stock option exercises.

Income Taxes

Plan of Operation

General Overview of Plans

The Company’s original focus was the development of new treatments for the most common and most aggressive type of brain cancer of adults, glioblastoma multiforme (“GBM”), and the most common cancer of children, neuroblastoma. The Company has expanded the scope of its anti-cancer investigational activities to include the most common brain tumor of children, medulloblastoma, and also to several other types of more common cancers. This expansion of activity is based on documentation that each of two distinct types of drugs being developed by the Company has activity against cell lines of breast, colon, lung, prostate, pancreas, ovary, stomach and liver cancer, as well as against the major types of leukemias. LB-100 has now been shown to have activity in animal models of brain tumors of adults and children, and also against melanomas and sarcomas. Studies in animal models of human melanoma, lymphoma, sarcoma, brain tumors, and the rare neuroendocrine cancer, pheochromocytoma, have demonstrated marked potentiation by LB-100 of the anti-tumor activity of the widely used standard chemotherapeutic drugs. These studies confirm that the LB-100 compounds, in combination with any of several standard anti-cancer drugs, have broad activity affecting many different cell types of cancer. This is unusual and significant because these compounds may be useful for treatment of cancer in general.

The Company’s immediate focus has been to determine the safety and appropriate dose of LB-100 when used alone and in combination with widely used anti-cancer drugs in its Phase 1 clinical trial. The Company’s longer-term objective is to secure one or more strategic partnerships with pharmaceutical companies with major programs in cancer, vascular disease and/or neurologic disease.

The significant diversity of the potential therapeutic value of the Company’s Series 2 compounds (LB-201 and homologs) stems from the fact that these agents modify critical pathways in cancer cells and in microorganisms such as fungi, and appear to ameliorate pathologic processes that lead to brain injury caused by trauma or toxins or through as yet unknown mechanisms that underlie the major chronic neurologic diseases, including Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s disease).

Operating Plans

The Company’s primary focus is developing new treatments for human cancers for which better therapies are urgently needed. The scope of potential applications of the Company’s products has expanded to other common non-malignant diseases, including vascular diseases (heart attacks and stroke), diabetes, genetic diseases, such as Gaucher’s disease, and recently to depression and potentially post-traumatic stress syndrome. This has occurred because the targets selected by the Company have multiple functions in the cell, which, when altered, result in different disorders that may benefit by treatment from the Company’s products.

The Company’s drug discovery process is based on discerning clues to potential new targets for disease treatments reported in the increasingly large body of literature identifying the molecular variants which characterize human cancers and other non-cancer disorders. The Company designs drugs for which there are existing data suggesting that they may affect the altered pathways of the cancer cell and may be given safely to humans. The Company seeks to rapidly arrive at patentable structures through analysis of the literature rather than screening of thousands of structures for activity against a particular biochemical pathway.

This approach has led to the development of two classes of drugs for the treatment of cancer, consisting of protein phosphatase inhibitors (PTase-i), designated by the Company as the LB-100 series of compounds, and histone deacetylase inhibitors (HDACi), designated by the Company as the LB-200 series of compounds. Compounds of both types also have potential use in the prevention and treatment of neurodegenerative diseases.

The LB-100 series consists of novel structures, which have the potential to be first in their class, and may be useful in the treatment of not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds which have the potential to be the most effective in its class and may be useful for the treatment of chronic hereditary diseases, such as Gaucher’s disease, in addition to cancer and neurodegenerative diseases.

The Company has demonstrated that lead compounds of both series of drugs are active against a broad spectrum of human cancers in cell culture and against several types of human cancers in animal models. The research on new drug treatment was initiated in 2006 with the National Institute of Neurological Disorders and Stroke (“NINDS”) of the National Institutes of Health (“NIH”) under a Cooperative Research and Development Agreement (“CRADA”) effective March 22, 2006. The research at NINDS was led by Dr. Zhengping Zhuang, an internationally recognized investigator in the molecular pathology of cancer. The initial focus of the CRADA was on the most common and uniformly fatal brain tumor of adults, GBM. The work at NIH was then extended to the most common brain tumor of children, medulloblastoma, and to the most common extracranial solid tumor of children, neuroblastoma. The CRADA was extended through a series of amendments and remained in effect until April 1, 2013, when it terminated as scheduled.

Effective October 18, 2013, the Company entered into a Materials Cooperative Research and Development Agreement (M-CRADA) with the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NINDS, NIH) for a term of four years. The Surgical Neurology Branch of NINDS, NIH will conduct research characterizing a variety of compounds proprietary to the Company, and will examine the compounds’ potential for anti-cancer activity, reducing neurological deficit due to ischemia and brain injury, and stabilizing catalytic function of misfolded proteins for inborn brain diseases. Under an M-CRADA, a party provides research material, in this case proprietary compounds from the Company’s pipeline, for study by scientists at NIH. The exchange of material is for research only and implies no endorsement of the material on the part of either party. Under the M-CRADA the NIH grants a collaborator an exclusive option to elect an exclusive or non-exclusive commercialization license. The M-CRADA does not generate any incremental cost to the Company.

Effective treatment of brain tumors depends upon the ability of compounds to penetrate a physiological barrier known as the “blood-brain barrier”, which protects the brain from exposure to potentially toxic substances in the blood. Because there is no certainty that the Company’s compounds will be active against tumors confined to the brain, the LB-100 compounds have been studied against a variety of common and rare cancer types and have been shown to potentiate the activity of standard anti-cancer drugs in animal models of breast and pancreatic cancer, melanoma, pheochromcytomas and sarcomas. Because the LB-100 compounds appear to exert their ability to improve the effectiveness of different forms of chemotherapy and radiation therapy by inhibiting a process upon which most, if not all, cancer cell types depend on to survive treatment, the Company believes the LB-100 series of compounds may be useful against most, if not all, cancer types.

The second class of drugs under development by the Company, referred to as LB-200, is the histone deacetylase inhibitors. Many pharmaceutical companies are also developing drugs of this type, and at least two companies have HDACi approved for clinical use, in both cases for the treatment of a type of lymphoma. Despite this significant competition, the Company has demonstrated that its HDACi has broad activity against many cancer types, has neuroprotective activity, and has anti-fungal activity. In addition, these compounds have low toxicity, making them attractive candidates for development. It appears that one type of molecule has diverse effects, affecting biochemical processes that are fundamental to the life of the cell, whether they are cancer cells, nerve cells, or even fungal cells. The neuroprotective activity of the Company’s HDACi has been demonstrated in the test tube in model systems that mimic injury to brain cells, such as occurs in stroke and Alzheimer’s disease. This type of protective activity may have potential application to a broad spectrum of other chronic neurodegenerative diseases, including Parkinson’s disease and Amytrophic Lateral Sclerosis (ALS, or Lou Gehrig’s disease).

The Company’s primary objective has been to bring one lead compound of the LB-100 series to clinical trial. In 2012, the Company completed the pre-clinical studies required to prepare an Investigational New Drug (“IND”) application to the United States Food and Drug Administration (“FDA”) to conduct a Phase 1 clinical trial of LB-100, and engaged Theradex Systems, Inc. (“Theradex”), an international contract research organization (“CRO”) that provides professional services for the clinical research and development of pharmaceutical compounds, to be responsible for the clinical development of the Company’s lead compound, LB-100, and to prepare an IND application for filing with the FDA.

The Company filed an IND application with the FDA on April 30, 2012, and on July 24, 2012, the FDA notified the Company that it would allow initiation of a Phase 1 clinical trial of LB-100. The purpose of this clinical trial was to demonstrate that LB-100 can be administered safely to human beings at a dose and at a frequency that achieves the desired pharmacologic effect; in this case, inhibition of a specific enzyme, without being associated with toxicities considered unacceptable. The Phase 1 clinical trial of LB-100 was designed to be conducted in two parts. In Part 1, the maximum tolerable dose (“MTD”) of LB-100 was to be determined. In Part 2, the MTD of LB-100, in combination with the standard cytotoxic drug docetaxel (which is a well-established anti-mitotic chemotherapy medication approved by the FDA for the treatment of various cancers), was to be determined.

The Phase 1 clinical trial of LB-100 began in April 2013 with the entry of patients into the clinical trial initiated at the City of Hope National Medical Center in Duarte, California, and was extended in December 2013 to include the Mayo Clinic in Rochester, Minnesota, both of which are Comprehensive Cancer Centers designated by the National Cancer Institute. As the accrual of patients was slower than anticipated, in October 2014, the Company entered into a Clinical Research Agreement (“CRA”) with US Oncology Research, LLC, a large community-based research network based in Texas, to increase the rate of entry of patients into the clinical trial by adding four more active clinical oncologic research sites.

The costs of Part 1 of the Phase 1 clinical trial have exceeded the Company’s original estimates, in part because patients were able to tolerate higher doses of LB-100 than originally expected, thus requiring more dose escalation steps to determine the MTD of LB-100 given alone. In addition, patients have been achieving stabilization without any dose-limiting toxicity (“DLT”), remaining on treatment with LB-100 for longer periods of time than is usual in a Phase 1 clinical trial of a new drug in patients failing all previous treatments. The Company’s interpretation of the clinical trial results to date is that LB-100 as a single agent has activity against several types of cancer, as evidenced by stabilization of progressive disease in the absence of DLT. The Company is continuing to administer LB-100 to patients if there is no cancer progression and the patient feels well and has no significant toxicity.

As a prelude to determining the therapeutic effectiveness of LB-100 in a subsequent Phase 2 clinical trial of common cancers, a key goal of Part 1 of the Phase 1 clinical trial was to demonstrate that the target enzyme of LB-100, protein phosphatase 2A (“PP2A”), can be inhibited in humans with readily tolerable toxicity. Part 1 of the current Phase 1 clinical trial of LB-100 is now concluding with the entry of three patients into the study to facilitate pharmacokinetic studies to determine the MTD. Two patients have been entered and a third patient will be entered shortly. As an anti-cancer drug, LB-100 is likely to be used at maximum tolerable doses. However, for the potential treatment of non-malignant diseases, such as acute vascular diseases and metabolic diseases, lower doses may achieve therapeutic benefit by inhibition of the target enzyme, PP2A, thus opening up the possibility of a host of therapeutic applications for LB-100 and related proprietary compounds.

As this is an experimental treatment not reimbursable by medical insurance, the cost of continuing treatment beyond the standard two cycles (one cycle is defined as the administration of the drug daily for three days every three weeks) that are required for the assessment of toxicity at a given dose level has been more than double the expected cost.

The costs of the Phase 1 clinical trial of LB-100 are being paid to or through Theradex, the CRO responsible for the clinical development of LB-100. Total costs charged to operations through March 31, 2016 for services paid to or through Theradex pursuant to this arrangement, which were first incurred in 2013, aggregated $1,774,276, of which $113,551 and $350,601 were incurred during the three months ended March 31, 2016 and 2015, respectively.

The Company had planned to proceed with Part 2 of the Phase 1 clinical trial to determine the toxicity of LB-100 in combination with docetaxel against a specific solid tumor for which single agent docetaxel is indicated. However, two developments have altered this plan. LB-100 appears to have anti-cancer activity in its own right, and second, preclinical studies indicate that LB-100 in combination with cisplatin (a widely used cytotoxic drug) is more active than LB-100 in combination with docetaxel. LB-100 significantly potentiates the standard anti-cancer drug cisplatin in animal models of several tumor types, including hepatocellular cancer and platinum-resistant ovarian cancer. In addition, it has been reported that inhibition of the enzyme-target of LB-100, PP2A, inhibits certain variants of the hematologic disorder known as myelodysplastic syndrome (“MDS”). Accordingly, the Company has decided not to proceed with Part 2 of the Phase 1 clinical trial, and has initiated planning for Phase1b/2 clinical trials in 2016 to evaluate the effectiveness of LB-100 alone for the treatment of MDS and in combination with a platinum compound for the treatment of platinum-resistant ovarian cancer.

The Company estimates that Part 1 of the Phase 1 clinical trial of LB-100 will now cost a total of approximately $2,200,000 and is estimated to be completed by May 31, 2016, as compared to the Company’s previous estimate of a total cost of approximately $1,800,000 and a completion date of December 31, 2015. The following factors have contributed to the most recent revisions to the total cost and completion date of this clinical trial: (1) some patients are continuing to receive the study compound longer than is usual for patients with treatment-refractory progressive disease in a Phase 1 clinical trial; (2) the establishment of the MTD required more subjects than the initially planned six patients; and (3) the planned pharmacokinetic studies required more than the initially planned three patients.

As a compound moves through the FDA approval process, it becomes an increasingly valuable property, but at a cost of additional investment at each stage. As the potential effectiveness of LB-100 has been documented at the clinical trial level, the Company has allocated resources to expand the depth and extent of its patent portfolio. The Company’s approach has been to operate with a minimum of overhead, moving compounds forward as efficiently and inexpensively as possible, and to raise funds to support each of these stages as certain milestones are reached.

Results of Operations

At March 31, 2016, the Company had not yet commenced any sustainable revenue-generating operations, does not have any positive cash flows from operations, and is dependent on its ability to raise equity capital to fund its operating requirements.

The Company’s condensed consolidated statements of operations as discussed herein are presented below.

	Three Months Ended March 31,
	2016			2015

Licensing revenues	$	—		$	—

Costs and expenses:
General and administrative costs		152,057			246,643
Research and development costs		264,497			505,514
Total costs and expenses		416,554			752,157
Loss from operations		(416,554	)		(752,157	)
Interest income		11			11
Fair value of warrant extensions		—			(34,016	)
Fair value of warrant discount		—			(171,757	)
Net loss		(416,543	)		(957,919	)
Dividend on Series A Convertible Preferred Stock		—			—
Net loss attributable to common stockholders	$	(416,543	)	$	(957,919	)

Net loss per common share – basic and diluted	$	(0.01	)	$	(0.02	)

Weighted average common shares outstanding – basic and diluted		47,875,814			45,498,550

Three Months Ended March 31, 2016 and 2015

Licensing Revenues. The Company did not have any licensing revenues for the three months ended March 31, 2016 and 2015.

General and Administrative. For the three months ended March 31, 2016, general and administrative costs were $152,057, which consisted of consulting and professional fees of $104,553, insurance expense of $14,915, officer’s salary and related costs of $16,967, stock transfer fees of $2,937, filing fees of $5,598, travel and entertainment costs of $2,897, and other operating costs of $4,190.

For the three months ended March 31, 2015, general and administrative costs were $246,643, which consisted of the fair value of stock options issued to directors and consultants of $81,678, consulting and professional fees of $122,286, insurance expense of $13,825, officer’s salary and related costs of $17,018, stock transfer fees of $3,143, filing fees of $149, travel and entertainment costs of $3,561, and other operating costs of $4,983.

General and administrative costs decreased by $94,586 or 38.3% in 2016 as compared to 2015, primarily as a result of a decrease of $81,678 in stock-based compensation.

A significant component of the fair value of stock options issued to directors and consultants of $81,678 for the three months ended March 31, 2015 was $74,901 charged to operations for the fair value of stock options to acquire 4,000,000 shares of the Company’s common stock that were issued to Gil Schwartzberg on January 28, 2014 for his continuing contributions to the Company’s financial strategy, which were fully amortized as of March 31, 2015.

Research and Development. For the three months ended March 31, 2016, research and development costs were $264,497, which consisted of a credit for the vested portion of the fair value of common stock options and warrants of $(30,370), patent costs of $101,956, and contractor costs of $192,911, including $113,551 to Theradex in connection with the Phase 1 clinical trial of LB-100. Contractor costs during the three months ended March 31, 2016 also include $60,174 incurred with other vendors primarily in connection with the Company’s pre-clinical research focused on the development of additional novel anti-cancer compounds to add to its clinical pipeline. The Phase 1 clinical trial of LB-100 is estimated to be completed by May 31, 2016.

The credit for the vested portion of the fair value of common stock options and warrants of $(30,370) for the three months ended March 31, 2016 was primarily attributable to a decline in the Company’s stock price from December 31, 2015 through March 31, 2016.

For the three months ended March 31, 2015, research and development costs were $505,514, which consisted of the vested portion of the fair value of stock options of $2,316, patent costs of $127,481, and contractor costs of $375,717, including $350,601 to Theradex in connection with the Phase 1 clinical trial of LB-100.

Research and development costs decreased by $241,017 or 47.7% in 2016 as compared to 2015, primarily as a result of a decrease of $25,525 in patent costs incurred to protect the Company’s patent portfolio, and $182,806 in contractor costs, including a decrease of $237,050 to Theradex, in connection with the Phase 1 clinical trial of LB-100 (which is winding down and is estimated to be completed by May 31, 2016), offset by an increase of $60,174 in costs attributed to the Company’s continuing pre-clinical research focused on the development of additional novel anti-cancer compounds..

Fair Value of Warrant Extensions. During the three months ended March 31, 2015, the Company incurred an expense of $34,016 for the fair value of extending the expiration dates of warrants to acquire 2,928,800 shares of common stock from March 31, 2015 to April 15, 2015. During the three months ended March 31, 2016, the Company did not incur any warrant extension costs.

Fair Value of Warrant Discount. During the three months ended March 31, 2015, the Company incurred an expense of $171,757 for the fair value of discounts offered to warrant holders as an inducement for the early exercise of warrants to acquire 2,928,800 shares of common stock. The discounts ranged from $0.25 to $0.375 per share. The subsequent exercise of warrants resulted in the issuance of 1,050,000 shares of common stock and generated net proceeds to the Company of $315,000 in April 2015. During the three months ended March 31, 2016, the Company did not incur any warrant discount costs.

Net Loss. For the three months ended March 31, 2016, the Company incurred a net loss of $416,543, as compared to a net loss of $957,919 for the three months ended March 31, 2015.

Dividends on Series A Convertible Preferred Stock. The Company did not recognize any dividends on its Series A Convertible Preferred Stock for the three months ended March 31, 2016 and 2015.

Net Loss Attributable to Common Stockholders. For the year three months ended March 31, 2016, the Company incurred a net loss attributable to common stockholders of $416,543, as compared to a net loss attributable to common stockholders of $957,919 for the three months ended March 31, 2015.

Liquidity and Capital Resources – March 31, 2016

At March 31, 2016, the Company had working capital of $1,032,088 (including advances on research and development contract services of $200,398), as compared to working capital of $322,333 at December 31, 2015 (including a licensing fee receivable of $200,000 and advances on research and development contract services of $207,677), an increase in working capital of $709,755 for the three months ended March 31, 2016. The increase in working capital is primarily the net result of the proceeds received from subscription payments of $1,166,668 relating to the sale on January 20, 2016 of 175,000 shares of the Company’s non-voting Series A Convertible Preferred Stock at a price per share of $10.00, for an aggregate subscription price of $1,750,000, which is being utilized to fund the Company’s Phase 1 clinical trial and its ongoing operating expenses, including maintaining its patent portfolio. At March 31, 2016, the Company had cash and money market funds aggregating $970,159, as compared to $129,376 at December 31, 2015, an increase of $840,783 for the three months ended March 31, 2016.

At March 31, 2016, the Company had advances made to or through Theradex aggregating $183,063, of which $181,510 is expected to be refunded to the Company once the Company’s Phase 1 clinical trial of LB-100 is completed.

As a result of the Company entering into an agreement in January 2016 to sell additional shares of preferred stock for aggregate cash proceeds of $1,750,000 to be received by June 3, 2016, and the licensing proceeds received during the three months ended March 31, 2016, the Company believes that it has sufficient funds to complete the Phase 1 clinical trial of its lead anti-cancer compound LB-100, to conduct a Phase 1b/2 clinical trial of LB-100 in the hematologic disorder known as myelodysplastic syndrome, and to support its ongoing operating expenses, including maintaining its patent portfolio, through mid-2017.

The amount and timing of future cash requirements depend on the pace and design of the Company’s clinical trial program. The Company currently plans to attempt to raise an additional approximately $3,000,000 of capital in the second half of 2016, likely in the form of equity, to also conduct a Phase 1b/2 clinical trial of LB-100 in combination with a platinum compound in platinum-resistant ovarian cancer and to extend the Company’s pre-clinical research on compounds in its pipeline.

Operating Activities. For the three months ended March 31, 2016, operating activities utilized cash of $325,885, as compared to utilizing cash of $538,634 for the three months ended March 31, 2015, to fund the Company’s Phase 1 clinical trial, to support its other ongoing research and development activities, and to fund its other ongoing operating expenses, including maintaining its patent portfolio.

Investing Activities. For the three months ended March 31, 2016, investing activities consisted of a increase in money market funds of $766,678, due primarily to the receipt of subscription payments totaling $1,166,668 relating to the sale on January 20, 2016 of 175,000 shares of the Company’s Series A Convertible Preferred Stock at an aggregate purchase price of $1,750,000. For the three months ended March 31, 2015, investing activities consisted of an increase in money market funds of $1,103,068 due primarily to the sale of 175,000 shares of the Company’s Series A Convertible Preferred Stock at an aggregate purchase price of $1,750,000 on March 17, 2015.

Financing Activities. For the three months ended March 31, 2016, financing activities consisted of the receipt of subscription payments totaling $1,166,668 relating to the sale on January 20, 2016 of 175,000 shares of the Company’s Series A Convertible Preferred Stock at an aggregate purchase price of $1,750,000. For the three months ended March 31, 2015, financing activities consisted of $1,750,000 in proceeds received from the sale of 175,000 shares of the Company’s Series A Convertible Preferred Stock at an aggregate purchase price of $1,750,000 on March 17, 2015, less costs of $12,608 associated with the sale.

Principal Commitments

Effective January 1, 2014, the Company entered into an Advisory Agreement with Dr. Kathleen P. Mullinix, a member of the Board of Directors of the Company, effective for an initial term of one year through December 31, 2014 to advise on business development matters. The Advisory Agreement provided for annual cash compensation of $25,000. The term of the Advisory Agreement was automatically extended for a term of one year annually unless a notice of intent to terminate was given by either party at least 90 days before the end of the applicable term. Accordingly, the Advisory Agreement was extended for additional terms of one year effective January 1, 2015 and 2016. The Company recognized a charge to operations of $6,250 as consulting and advisory fees pursuant to this Advisory Agreement during the three months ended March 31, 2016 and 2015.

Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged BioPharmaWorks to perform certain services for the Company. Those services include, among other things: (a) assisting the Company to (i) commercialize its products and strengthen its patent portfolio, (ii) identify large pharmaceutical companies with potential interest in the Company’s product pipeline, and (iii) prepare and deliver presentations concerning the Company’s products; (b) at the request of the Board of Directors, serving as backup management for up to three months should the Company’s Chief Executive Officer and scientific leader be temporarily unable to carry out his duties; (c) being available for consultation in drug discovery and development; and (d) identifying providers and overseeing tasks relating to clinical use and commercialization of new compounds. BioPharmaWorks was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience. The Collaboration Agreement is for an initial term of two years and automatically renews for subsequent annual periods unless terminated by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the Company agreed to pay BioPharmaWorks a monthly fee of $10,000, subject to the right of the Company to pay a negotiated hourly rate in lieu of the monthly payment, and agreed to issue to BioPharmaWorks certain equity-based compensation. Fees charged to operations pursuant to this Collaboration Agreement was $30,000 during the three months ended March 31, 2016.

			Payments Due By Year
	Total		2016		2017		2018		2019		2020

Research and development contracts	$	41,004	$	41,004	$	—	$	—	$	—	$	—
Clinical trial agreements		256,910		256,910		—		—		—		—
Consulting agreements		197,000		107,000		90,000		—		—		—
Total	$	494,914	$	404,914	$	90,000	$	—	$	—	$	—

Off-Balance Sheet Arrangements

At March 31, 2016, the Company did not have any transactions, obligations or relationships that could be considered off-balance sheet arrangements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures

The Company carried out an evaluation, under the supervision and with the participation of its management, consisting of its principal executive officer and principal financial officer (who is the same person), of the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act (defined below)). Based upon that evaluation, the Company’s principal executive officer and principal financial officer concluded that, as of the end of the period covered in this report, the Company’s disclosure controls and procedures were effective to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to the Company’s management, consisting of the Company’s principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.

The Company’s management, consisting of its principal executive officer and principal financial officer, does not expect that its disclosure controls and procedures or its internal controls will prevent all error or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Furthermore, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. In addition, as conditions change over time, so too may the effectiveness of internal controls. However, management believes that the financial statements included in this report fairly present, in all material respects, the Company’s financial condition, results of operations and cash flows for the periods presented.

(b) Changes in Internal Controls Over Financial Reporting

The Company’s management, consisting of its principal executive officer and principal financial officer, has determined that no change in the Company’s internal control over financial reporting (as that term is defined in Rules 13(a)-15(f) and 15(d)-15(f) of the Securities Exchange Act of 1934) occurred during or subsequent to the end of the period covered in this report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company is not currently subject to any pending or threatened legal actions or claims.

ITEM 1A. RISK FACTORS

As of the date of this filing, there have been no material changes to the Risk Factors included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015, as filed with the SEC on March 28, 2016 (the “2015 Form 10-K”). The Risk Factors set forth in the 2015 Form 10-K should be read carefully in connection with evaluating the Company’s business and in connection with the forward-looking statements contained in this Quarterly Report on Form 10-Q. Any of the risks described in the 2015 Form 10-K could materially adversely affect the Company’s business, financial condition or future results and the actual outcome of matters as to which forward-looking statements are made. These are not the only risks that the Company faces. Additional risks and uncertainties not currently known to the Company or that the Company currently deems to be immaterial also may materially adversely affect the Company’s business, financial condition and/or operating results.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

This class of Preferred Stock has a dividend per share equal to 1% of the annual net revenue of the Company divided by 175,000, until converted or redeemed.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

ITEM 6. EXHIBITS

A list of exhibits required to be filed as part of this report is set forth in the Index to Exhibits, which is presented elsewhere in this document, and is incorporated herein by reference.

SIGNATURES

In accordance with the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	LIXTE BIOTECHNOLOGY HOLDINGS, INC.
	(Registrant)

Date: May 6, 2016	By:	/s/ JOHN S. KOVACH
		John S. Kovach
		Chief Executive Officer and Chief Financial Officer
		(Principal financial and accounting officer)

INDEX TO EXHIBITS

The following documents are filed as part of this report:

Exhibit Number		Description of Document

3.1		Certificate of Amendment of Certificate of Designations of the Series A Convertible Preferred Stock, incorporated by reference to Exhibit 3.4 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015, as filed with the Securities and Exchange Commission on March 28, 2016.

31.1*		Officer’s Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Officer’s Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS**		XBRL Instance Document

101.SCH**		XBRL Taxonomy Extension Schema Document

101.CAL**		XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB**		XBRL Taxonomy Extension Label Linkbase Document

101.PRE**		XBRL Taxonomy Extension Presentation Linkbase Document

101.DEF**		XBRL Taxonomy Extension Definition Linkbase Document

* Filed herewith.

** In accordance with Regulation S-T, the XBRL related information on Exhibit No. 101 to this Quarterly Report on Form 10-Q shall be deemed “furnished” herewith but not “filed”.

EX-31.1 2 ex31-1.htm

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John S. Kovach, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Lixte Biotechnology Holdings, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s Board of Directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 6, 2016	By:	/s/ JOHN S. KOVACH
		John S. Kovach
		Chief Executive Officer and Chief Financial Officer

EX-32.1 3 ex32-1.htm

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, John S. Kovach, the Chief Executive Officer and Chief Financial Officer of Lixte Biotechnology Holdings, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

(i) The Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2016 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

(ii) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Date: May 6, 2016	By:	/s/ JOHN S. KOVACH
		John S. Kovach
		Chief Executive Officer and Chief Financial Officer

EX-101.INS 4 lixt-20160331.xml XBRL INSTANCE FILE 0001335105 2016-01-01 2016-03-31 0001335105 2015-12-31 0001335105 2016-03-31 0001335105 us-gaap:StockOptionMember 2016-01-01 2016-03-31 0001335105 us-gaap:StockOptionMember 2015-01-01 2015-03-31 0001335105 LIXT:ExercisePriceOneMember 2016-03-31 0001335105 LIXT:ExercisePriceTwoMember 2016-03-31 0001335105 us-gaap:MoneyMarketFundsMember 2015-12-31 0001335105 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2015-12-31 0001335105 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2015-12-31 0001335105 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2015-12-31 0001335105 us-gaap:MoneyMarketFundsMember 2016-03-31 0001335105 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2016-03-31 0001335105 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2016-03-31 0001335105 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2016-03-31 0001335105 LIXT:TheradexSystemsIncMember 2013-01-01 2016-03-31 0001335105 LIXT:TheradexSystemsIncMember 2016-01-01 2016-03-31 0001335105 us-gaap:MinimumMember 2016-01-01 2016-03-31 0001335105 us-gaap:MaximumMember 2016-01-01 2016-03-31 0001335105 LIXT:ConsultingArrangementsMember LIXT:MrSchwartzbergMember 2014-01-28 0001335105 LIXT:ConsultingArrangementsMember LIXT:MrSchwartzbergMember 2014-01-27 2014-01-28 0001335105 LIXT:ConsultingArrangementsMember LIXT:MrSchwartzbergMember 2015-01-28 0001335105 LIXT:NdaConsultingCorpAgreementMember 2013-12-24 0001335105 LIXT:NdaConsultingCorpAgreementMember LIXT:VestingOnJuneTwentyFourTwentySixteenMember 2013-12-24 0001335105 LIXT:NdaConsultingCorpAgreementMember LIXT:VestingOnJuneTwentyFourTwentySeventeenMember 2013-12-24 0001335105 LIXT:NdaConsultingCorpAgreementMember 2013-12-23 2013-12-24 0001335105 LIXT:NdaConsultingCorpAgreementMember 2016-01-01 2016-03-31 0001335105 LIXT:ExercisePriceThreeMember 2016-03-31 0001335105 LIXT:ExercisePriceFourMember 2016-03-31 0001335105 LIXT:ExercisePriceFiveMember 2016-03-31 0001335105 LIXT:ExercisePriceSixMember 2016-03-31 0001335105 LIXT:PaymentsDueByTwoThousandNineTeenMember 2016-03-31 0001335105 LIXT:PaymentsDueByTwoThousandTwentyMember 2016-03-31 0001335105 LIXT:PaymentsDueByTwoThousandSixteenMember 2016-03-31 0001335105 LIXT:PaymentsDueByTwoThousandSeventeenMember 2016-03-31 0001335105 LIXT:PaymentsDueByTwoThousandEighteenMember 2016-03-31 0001335105 LIXT:TheradexSystemsIncMember LIXT:PhaseOneClinicalMember 2016-01-01 2016-03-31 0001335105 LIXT:Dr.KovachMember 2014-12-31 0001335105 LIXT:Dr.KovachMember 2015-03-17 0001335105 2016-04-29 0001335105 LIXT:CommonStockWarrantsMember 2016-01-01 2016-03-31 0001335105 LIXT:CommonStockWarrantsMember 2015-01-01 2015-03-31 0001335105 LIXT:Dr.KovachMember 2016-01-01 2016-03-31 0001335105 LIXT:Dr.KovachMember 2015-01-01 2015-03-31 0001335105 LIXT:TwoThousandSevenStockCompensationPlanMember 2007-06-19 2007-06-20 0001335105 LIXT:TwoThousandSevenStockCompensationPlanMember 2016-01-01 2016-03-31 0001335105 LIXT:AndrewRobellMember LIXT:AdvisoryAgreementMember 2014-10-06 2014-10-07 0001335105 LIXT:AndrewRobellMember LIXT:AdvisoryAgreementMember 2014-10-07 0001335105 LIXT:AndrewRobellMember LIXT:AdvisoryAgreementMember 2015-10-07 0001335105 LIXT:TwoThousandSevenStockCompensationPlanMember 2016-03-31 0001335105 us-gaap:CommonStockMember 2015-12-31 0001335105 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001335105 us-gaap:RetainedEarningsMember 2015-12-31 0001335105 LIXT:SeriesAConvertiblePreferredStockMember 2016-03-31 0001335105 LIXT:TheradexSystemsIncMember 2015-01-01 2015-03-31 0001335105 LIXT:SeriesAConvertiblePreferredStockMember 2015-01-01 2015-03-31 0001335105 LIXT:NonVotingSeriesAConvertiblePreferredStockMember 2015-03-17 0001335105 us-gaap:PreferredStockMember 2016-03-31 0001335105 2015-03-16 2015-03-17 0001335105 LIXT:NonVotingSeriesAConvertiblePreferredStockMember 2015-03-16 2015-03-17 0001335105 LIXT:WarrantEightMember 2015-03-05 2015-03-06 0001335105 LIXT:WarrantsExtensionsFourMember 2015-03-04 2015-03-06 0001335105 LIXT:WarrantsExtensionsFourMember 2015-03-06 0001335105 LIXT:WarrantsExtensionsFourMember us-gaap:MinimumMember 2015-03-06 0001335105 LIXT:WarrantsExtensionsFourMember us-gaap:MaximumMember 2015-03-06 0001335105 LIXT:WarrantsExtensionsFourMember us-gaap:MinimumMember 2015-03-05 2015-03-06 0001335105 LIXT:WarrantsExtensionsFourMember us-gaap:MaximumMember 2015-03-04 2015-03-06 0001335105 LIXT:WarrantsExtensionsFiveMember 2015-03-04 2015-03-06 0001335105 LIXT:WarrantsExtensionsFiveMember 2015-03-06 0001335105 LIXT:MinimumOneMember LIXT:WarrantsExtensionsFiveMember 2015-03-06 0001335105 LIXT:MaximumOneMember LIXT:WarrantsExtensionsFiveMember 2015-03-06 0001335105 LIXT:WarrantsExtensionsSixMember 2015-03-05 2015-03-06 0001335105 LIXT:WarrantsExtensionsSixMember us-gaap:MinimumMember 2015-03-06 0001335105 LIXT:WarrantsExtensionsSixMember us-gaap:MaximumMember 2015-03-06 0001335105 LIXT:ConsultingArrangementsMember LIXT:MrSchwartzbergMember 2015-01-01 2015-03-31 0001335105 LIXT:NdaConsultingCorpAgreementMember 2015-01-01 2015-03-31 0001335105 2015-01-01 2015-03-31 0001335105 us-gaap:MinimumMember 2015-01-01 2015-03-31 0001335105 us-gaap:MaximumMember 2015-01-01 2015-03-31 0001335105 LIXT:Dr.KovachMember 2015-03-16 2015-03-17 0001335105 LIXT:WarrantsExtensionsSixMember 2015-03-06 0001335105 LIXT:AndrewRobellMember LIXT:VestedMember LIXT:AdvisoryAgreementMember 2014-10-06 2014-10-07 0001335105 LIXT:AdvisoryAgreementMember 2016-01-01 2016-03-31 0001335105 LIXT:AdvisoryAgreementMember 2015-01-01 2015-03-31 0001335105 LIXT:ProActiveCapitalResourcesGroupLLCMember 2014-10-06 2014-10-07 0001335105 LIXT:ProActiveCapitalResourcesGroupLLCMember 2014-10-07 0001335105 LIXT:ProActiveCapitalResourcesGroupLLCMember 2015-04-07 0001335105 LIXT:NDAConsultingCorpMember 2013-12-23 2013-12-24 0001335105 LIXT:NDAConsultingCorpMember 2015-01-01 2015-03-31 0001335105 LIXT:NDAConsultingCorpMember 2016-01-01 2016-03-31 0001335105 LIXT:WarrantsExtensionsFourMember LIXT:RangeOfWarrantsPriceZeroPointFiveZeroPricePerShareMember 2015-03-06 0001335105 LIXT:WarrantsExtensionsFourMember LIXT:RangeOfWarrantsPriceZeroPointSevenFivePricePerShareMember 2015-03-06 0001335105 LIXT:MinimumTwoMember LIXT:WarrantsExtensionsFiveMember 2015-03-06 0001335105 LIXT:MaximumTwoMember LIXT:WarrantsExtensionsFiveMember 2015-03-06 0001335105 LIXT:EricFormanMember 2016-01-01 2016-03-31 0001335105 LIXT:EricFormanMember 2015-01-01 2015-03-31 0001335105 LIXT:DrKathleenPMullinixMember 2014-01-01 2014-12-31 0001335105 LIXT:ChairmanAndMajorStockholderMember 2015-03-16 2015-03-17 0001335105 LIXT:ChairmanAndMajorStockholderMember 2015-03-17 0001335105 LIXT:BioPharmaWorksLLCMember 2015-09-13 2015-09-14 0001335105 LIXT:BioPharmaWorksLLCMember 2015-09-14 0001335105 LIXT:BioPharmaWorksLLCMember LIXT:FirstWarrantMember LIXT:SeptemberFourteenTwoThousandAndSixteenMember 2016-01-01 2016-03-31 0001335105 LIXT:BioPharmaWorksLLCMember LIXT:FirstWarrantMember LIXT:SeptemberFourteenTwoThousandAndSixteenMember 2016-03-31 0001335105 LIXT:BioPharmaWorksLLCMember LIXT:SecondWarrantMember LIXT:SeptemberFourteenTwoThousandAndSeventeenMember 2016-01-01 2016-03-31 0001335105 LIXT:BioPharmaWorksLLCMember LIXT:SecondWarrantMember LIXT:SeptemberFourteenTwoThousandAndSeventeenMember 2016-03-31 0001335105 LIXT:ExercisePriceSevenMember 2016-03-31 0001335105 LIXT:NdaConsultingCorpAgreementMember 2014-06-24 0001335105 LIXT:NdaConsultingCorpAgreementMember 2015-06-24 0001335105 LIXT:BioPharmaWorksLLCMember 2015-01-13 2015-09-14 0001335105 LIXT:DrKathleenMullinixMember 2016-01-01 2016-03-31 0001335105 LIXT:DrKathleenMullinixMember 2015-01-01 2015-03-31 0001335105 2016-01-01 2016-01-31 0001335105 LIXT:SecondHalfOfTwoThousandSixteenMember 2016-01-01 2016-03-31 0001335105 LIXT:TheradexSystemsIncMember 2016-03-31 0001335105 LIXT:TheradexSystemsIncMember LIXT:PhaseOneClinicalMember 2016-03-31 0001335105 LIXT:LicenseAgreementMember LIXT:TaipeiMedicalUniversityMember 2015-12-24 2015-12-25 0001335105 LIXT:LicenseAgreementMember LIXT:TaipeiMedicalUniversityMember LIXT:FirstPhaseOneBTwoClinicalTrialMember 2015-12-24 2015-12-25 0001335105 LIXT:LicenseAgreementMember LIXT:TaipeiMedicalUniversityMember LIXT:FirstPhaseThreeClinicalTrialMember 2015-12-24 2015-12-25 0001335105 LIXT:LicenseAgreementMember LIXT:TaipeiMedicalUniversityMember LIXT:FirstFilingOfNewDrugApplicationsMember 2015-12-24 2015-12-25 0001335105 LIXT:LicenseAgreementMember LIXT:TaipeiMedicalUniversityMember LIXT:CumulativeNetSalesMember 2015-12-24 2015-12-25 0001335105 LIXT:LicenseAgreementMember LIXT:TaipeiMedicalUniversityMember LIXT:NonSaleBasedSubLicenseIncomeMember us-gaap:MinimumMember 2015-12-24 2015-12-25 0001335105 LIXT:LicenseAgreementMember LIXT:TaipeiMedicalUniversityMember LIXT:NonSaleBasedSubLicenseIncomeMember us-gaap:MaximumMember 2015-12-24 2015-12-25 0001335105 LIXT:LicenseAgreementMember LIXT:TaipeiMedicalUniversityMember 2016-03-17 2016-03-18 0001335105 LIXT:JanuaryTwentyEightTwoThousandAndSixteenMember LIXT:SeriesAConvertiblePreferredStockMember us-gaap:MinimumMember 2016-03-31 0001335105 LIXT:JanuaryTwentyEightTwoThousandAndSixteenMember LIXT:SeriesAConvertiblePreferredStockMember us-gaap:MaximumMember 2016-03-31 0001335105 LIXT:WarrantsExtensionsSixMember LIXT:DrDebbieSchwartzbergMember 2015-03-05 2015-03-06 0001335105 LIXT:WarrantsExtensionsSixMember LIXT:PhilipFPalmedoMember 2015-03-05 2015-03-06 0001335105 LIXT:SecuritiesPurchaseAgreementMember 2016-03-03 2016-03-04 0001335105 LIXT:SecuritiesPurchaseAgreementMember LIXT:JuneThreeTwoThousandSixteenMember 2016-01-01 2016-03-31 0001335105 LIXT:DrFritzHennMember 2015-11-27 2015-11-28 0001335105 LIXT:DrFritzHennMember 2015-11-28 0001335105 LIXT:BioPharmaWorksLLCMember 2016-01-01 2016-03-31 0001335105 LIXT:SecuritiesPurchaseAgreementMember 2016-01-27 2016-01-28 0001335105 LIXT:SecuritiesPurchaseAgreementMember 2016-01-28 0001335105 us-gaap:PreferredStockMember 2016-01-21 0001335105 us-gaap:PreferredStockMember 2016-01-20 2016-01-21 0001335105 LIXT:ProActiveCapitalResourcesGroupLLCMember 2014-12-31 0001335105 LIXT:DrFritzHennMember LIXT:NovemberTwentyEightTwoThousandAndSixteenMember 2015-11-28 0001335105 LIXT:DrFritzHennMember 2016-01-01 2016-03-31 0001335105 LIXT:SeriesAConvertiblePreferredStockMember 2015-12-31 0001335105 LIXT:SeriesAConvertiblePreferredStockMember 2016-01-01 2016-03-31 0001335105 us-gaap:CommonStockMember 2016-01-01 2016-03-31 0001335105 us-gaap:CommonStockMember 2016-03-31 0001335105 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-03-31 0001335105 us-gaap:AdditionalPaidInCapitalMember 2016-03-31 0001335105 us-gaap:RetainedEarningsMember 2016-01-01 2016-03-31 0001335105 us-gaap:RetainedEarningsMember 2016-03-31 0001335105 LIXT:SeriesAConvertiblePreferredStockSubscriptionReceivableMember 2016-01-01 2016-03-31 0001335105 LIXT:SeriesAConvertiblePreferredStockSubscriptionReceivableMember 2015-12-31 0001335105 LIXT:SeriesAConvertiblePreferredStockSubscriptionReceivableMember 2016-03-31 0001335105 2015-03-31 0001335105 2014-12-31 0001335105 2015-01-01 2015-12-31 0001335105 LIXT:SecuritiesPurchaseAgreementMember 2015-01-01 2015-12-31 0001335105 LIXT:ProActiveCapitalResourcesGroupLLCMember 2015-04-01 2015-06-30 0001335105 LIXT:ProActiveCapitalResourcesGroupLLCMember 2016-01-01 2016-03-31 xbrli:shares iso4217:USD xbrli:shares iso4217:USD xbrli:pure P180M

12325000

7950000

6825000

2928800

2187500

11941300

4375000

The following table presents money market funds at their level within the fair value hierarchy at March 31, 2016 and December 31, 2015.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 1</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 2</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 3</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">March 31, 2016:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 44%; line-height: 115%">Money market funds</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%">870,773</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%">870,773</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">December 31, 2015:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Money market funds</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">104,095</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">104,095</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td></tr> </table>

A summary of stock option activity during the three months ended March 31, 2016 is presented in the tables below.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Weighted</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Average</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Weighted</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Remaining</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Number</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Average</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Contractual</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Of</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Exercise</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Life</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Shares</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Price</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">(in Years)</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 115%">Options outstanding at December 31, 2015</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 14%; text-align: right; line-height: 115%">7,950,000</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">0.697</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 14%; text-align: right; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Granted</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Exercised</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Expired</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Options outstanding at March 31, 2016</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">7,950,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">0.697</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">2.69</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Options exercisable at December 31, 2015</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">6,800,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">0.586</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Options exercisable at March 31, 2016</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">6,800,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">0.586</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">2.40</td> <td style="line-height: 115%"> </td></tr> </table>

The exercise prices of common stock options outstanding and exercisable are as follows at March 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Options</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Options</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center; line-height: 115%">Exercise</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Outstanding</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Exercisable</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Prices</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">(Shares)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">(Shares)</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 32%; text-align: right; line-height: 115%">0.130</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 2%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 29%; text-align: right; line-height: 115%">100,000</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 2%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 29%; text-align: right; line-height: 115%">50,000</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.250</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">500,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">500,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.500</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4,400,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4,300,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.650</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">700,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">700,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.980</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">250,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">250,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,500,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,000,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">2.000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">500,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">7,950,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">6,800,000</td> <td style="line-height: 115%"> </td></tr> </table>

10-Q 2016-03-31 false --12-31 Smaller Reporting Company

0.0001

0.001

0.0001

350000

10000000

175000

350000

175000

0.0001

100000000

47875814

101956 127481 2015-03-31 34016 171757 0.30 0.01 0.06 0.30

1853800

1075000

0.15

0.13

0.10

0.30

0.066

0.2568

0.2557

0.5168

0.00

1.9675

1.99

2.43

0.0001

0.0133

P2Y8M12D

P4Y8M12D

P25D

P40D

P15D

P3Y8M12D

P4Y6M

4000000

100000

550000

200000

250000

1000000

200000

P2Y4M24D

P5Y

P1Y

P5Y

0.586

0.50

0.13

0.50

0.25

0.26

0.50

2000000

25000

100000

125000

25000

100000

125000

100000

-30370

596400

12960

20000

10000

260000

298200

-10796

74901

2316

6777

-20733

1159

0.12

1.00

2.00

0.296

0.697

0.130

0.250

.500

.650

.980

1.000

2.000

7950000

100000

500000

4400000

700000

250000

1500000

500000

6800000

50000

500000

4300000

700000

250000

1000000

At March 31, 2016 and 2015, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31,</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 64%; line-height: 115%">Series A Convertible Preferred Stock</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 15%; text-align: right; line-height: 115%">4,375,000</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 15%; text-align: right; line-height: 115%">2,187,500</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Common stock warrants</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2,928,800</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Common stock options</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">7,950,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">6,825,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Total</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">12,325,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">11,941,300</td> <td style="line-height: 115%"> </td></tr> </table>

92717

47875814

41004 41004 256910 256910 197000 107000 90000 494914 404914 90000 <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="18" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Payments Due By Year</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2017</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2018</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2019</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2020</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; line-height: 115%">Research and development contracts</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 7%; text-align: right; line-height: 115%">41,004</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 7%; text-align: right; line-height: 115%">41,004</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 7%; text-align: right; line-height: 115%"></td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 7%; text-align: right; line-height: 115%"></td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 7%; text-align: right; line-height: 115%"></td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 7%; text-align: right; line-height: 115%"></td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Clinical trial agreements</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">256,910</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">256,910</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Consulting agreements</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">197,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">107,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">90,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Total</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">494,914</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">404,914</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">90,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td></tr> </table>

74901

12608

-30370

83994

2. Summary of Significant Accounting Policies   Principles of Consolidation   The accompanying condensed consolidated financial statements of the Company are prepared in accordance with United States generally accepted accounting principles (GAAP) and include the financial statements of Holdings and its wholly-owned subsidiary, Lixte. Intercompany balances and transactions have been eliminated in consolidation.   Use of Estimates   The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.   Cash Concentrations   The Companys cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date. The Company maintains its accounts with financial institutions with high credit ratings.    Research and Development   Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Companys treatments and product candidates.   Research and development costs are expensed ratably over the life of the underlying contracts, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. The costs of the Phase 1 clinical trial of LB-100 that are being paid through Theradex, the CRO, are recorded and expensed based upon the documentation provided by the CRO.   Payments made pursuant to research and development contracts are initially recorded as advances on research and development contract services in the Companys balance sheet and then charged to research and development costs in the Companys statement of operations as those contract services are performed. Expenses incurred under research and development contracts in excess of amounts advanced are recorded as research and development contract liabilities in the Companys balance sheet, with a corresponding charge to research and development costs in the Companys statement of operations. The Company reviews the status of its research and development contracts on a quarterly basis.   At March 31, 2016, the Company had advances made to or through Theradex aggregating $183,063, of which $181,510 is expected to be refunded to the Company upon completion of the Companys Phase 1 clinical trial of LB-100.   Patent Costs   Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Companys research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred. Patent costs were $101,956 and $127,481 for the three months ended March 31, 2016 and 2015, respectively. Patent costs are included in research and development costs in the Companys condensed consolidated statements of operations.   Accounting for Preferred Stock   The Company accounts for preferred stock as either equity or debt, depending on the specific characteristics of the security issued. The Series A Convertible Preferred Stock issued by the Company in January 2016 and March 2015 has been classified in stockholders equity, as described at Note 4.   Concentration of Risk   The Company periodically contracts with directors, including companies controlled by or associated with directors, to provide consulting services related to the Companys research and development and clinical trial activities. Agreements for these services can be for a specific time period (typically one year) or for a specific project or task, and can include both cash and non-cash compensation. The only such contract that represents 10% or more of general and administrative or research and development costs is described below.   On September 21, 2012, the Company entered into a work order agreement with Theradex, the CRO responsible for the clinical development of the Companys lead compound, LB-100, to manage and administer the Phase 1 clinical trial of LB-100. The Phase 1 clinical trial of LB-100, which began during April 2013 with the entry of patients into the clinical trial, is being carried out by nationally recognized comprehensive cancer centers, and is estimated to be completed by May 31, 2016.   The Phase 1 clinical trial is currently estimated to cost a total of approximately $2,200,000, with such payments expected to be allocated approximately 60% for services provided by Theradex and approximately 40% for pass-through costs for clinical center laboratory costs and investigator costs over the life of the clinical trial. Total costs charged to operations through March 31, 2016 for services paid to or through Theradex pursuant to this arrangement, which were first incurred in 2013, aggregated $1,774,276, of which $113,551 and $350,601 were incurred during the three months ended March 31, 2016 and 2015, respectively, or approximately 43% and 69% of research and development costs for the three months ended March 31, 2016 and 2015, respectively. Costs pursuant to this agreement are included in research and development costs in the Companys condensed consolidated statements of operations.    Income Taxes   The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities.   The Company has elected to deduct research and development costs on a current basis for federal income tax purposes. For federal tax purposes, start-up and organization costs were deferred until January 1, 2008 at which time the Company began to amortize such costs over a 180-month period.   The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made.   The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Companys net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of March 31, 2016 and 2015 and does not anticipate any material amount of unrecognized tax benefits within the next 12 months.   The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is more-likely-than-not to be sustained by the taxing authority as of the reporting date. If the tax position is not considered more-likely-than-not to be sustained, then no benefits of the position are recognized. As of March 31, 2016, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense.   Stock-Based Compensation   The Company periodically issues common stock and stock options to officers, directors, Scientific Advisory Committee members and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each grant.   The Company accounts for stock-based payments to officers and directors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Companys financial statements over the vesting period of the awards. The Company accounts for stock-based payments to Scientific Advisory Committee members and consultants by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached or (b) at the date at which the necessary performance to earn the equity instruments is complete.   Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.   Stock options granted to members of the Companys Scientific Advisory Committee and to outside consultants are revalued each reporting period to determine the amount to be recorded as an expense in the respective period. As the stock options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the value on the date of vesting.   The fair value of common stock issued as stock-based compensation is determined by reference to the closing price of the Companys common stock on the date of issuance. The fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award. Estimated volatility is based on the historical volatility of the Companys common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market value of common stock is determined by reference to the quoted market price of the Companys common stock.   The Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development costs, as appropriate, in the Companys condensed consolidated statement of operations. The Company issues new shares of common stock to satisfy stock option exercises.   Revenue Recognition   The Company recognizes revenue when all four of the following criteria are met: (i) persuasive evidence that an arrangement exists; (ii) delivery of the products and/or services has occurred; (iii) the fees earned can be readily determined; and (iv) collectability of the fees is reasonably assured.   Revenues from milestone payments under license agreements are recognized when earned and the Company has no further performance obligations thereunder.   Comprehensive Income (Loss)   Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). The Company did not have any items of comprehensive income (loss) for the three months ended March 31, 2016 and 2015.   Earnings (Loss) Per Share   The Companys computation of earnings (loss) per share (EPS) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares, warrants and stock options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.   Net income (loss) attributable to common stockholders consists of net income or loss, as adjusted for preferred stock dividends declared, amortized or accumulated.   Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all preferred shares, warrants and stock options outstanding are anti-dilutive.   At March 31, 2016 and 2015, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31,</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 64%; line-height: 115%">Series A Convertible Preferred Stock</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 15%; text-align: right; line-height: 115%">4,375,000</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 15%; text-align: right; line-height: 115%">2,187,500</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Common stock warrants</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2,928,800</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Common stock options</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">7,950,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">6,825,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Total</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">12,325,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">11,941,300</td> <td style="line-height: 115%"> </td></tr> </table>   Fair Value of Financial Instruments   The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required.   Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives.   Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges.   Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models.   The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end.   Money market funds are the only financial instrument that is measured and recorded at fair value on the Companys consolidated balance sheet on a recurring basis.   The carrying value of financial instruments (consisting of cash and accounts payable and accrued expenses) is considered to be representative of their respective fair values due to the short-term nature of those instruments.   Recent Accounting Pronouncements   In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. Based on the FASBs Exposure Draft Update issued on April 29, 2015, Revenue from Contracts With Customers (Topic 606): Deferral of the Effective Date, it is expected that ASU 2014-09 will now be effective for reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The adoption of ASU 2014-09 is not expected to have any impact on the Companys financial statement presentation or disclosures.   In August 2014, the FASB issued Accounting Standards Update No. 2014-15 (ASU 2014-15), Presentation of Financial Statements Going Concern (Subtopic 205-10). ASU 2014-15 provides guidance as to managements responsibility to evaluate whether there is substantial doubt about an entitys ability to continue as a going concern and to provide related footnote disclosures. In connection with preparing financial statements for each annual and interim reporting period, an entitys management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entitys ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). Managements evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued (or at the date that the financial statements are available to be issued when applicable). Substantial doubt about an entitys ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have any impact on the Companys financial statement presentation and disclosures.   In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The Company has not yet evaluated the impact of the adoption of ASU 2016-02 on the Companys financial statement presentation or disclosures.   Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Companys financial statement presentation or disclosures.

Principles of Consolidation   The accompanying condensed consolidated financial statements of the Company are prepared in accordance with United States generally accepted accounting principles (GAAP) and include the financial statements of Holdings and its wholly-owned subsidiary, Lixte. Intercompany balances and transactions have been eliminated in consolidation.

Cash Concentrations   The Companys cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date. The Company maintains its accounts with financial institutions with high credit ratings.

Research and Development   Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Companys treatments and product candidates.   Research and development costs are expensed ratably over the life of the underlying contracts, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. The costs of the Phase 1 clinical trial of LB-100 that are being paid through Theradex, the CRO, are recorded and expensed based upon the documentation provided by the CRO.   Payments made pursuant to research and development contracts are initially recorded as advances on research and development contract services in the Companys balance sheet and then charged to research and development costs in the Companys statement of operations as those contract services are performed. Expenses incurred under research and development contracts in excess of amounts advanced are recorded as research and development contract liabilities in the Companys balance sheet, with a corresponding charge to research and development costs in the Companys statement of operations. The Company reviews the status of its research and development contracts on a quarterly basis.   At March 31, 2016, the Company had advances made to or through Theradex aggregating $183,063, of which $181,510 is expected to be refunded to the Company upon completion of the Companys Phase 1 clinical trial of LB-100.

Concentration of Risk   The Company periodically contracts with directors, including companies controlled by or associated with directors, to provide consulting services related to the Companys research and development and clinical trial activities. Agreements for these services can be for a specific time period (typically one year) or for a specific project or task, and can include both cash and non-cash compensation. The only such contract that represents 10% or more of general and administrative or research and development costs is described below.   On September 21, 2012, the Company entered into a work order agreement with Theradex, the CRO responsible for the clinical development of the Companys lead compound, LB-100, to manage and administer the Phase 1 clinical trial of LB-100. The Phase 1 clinical trial of LB-100, which began during April 2013 with the entry of patients into the clinical trial, is being carried out by nationally recognized comprehensive cancer centers, and is estimated to be completed by May 31, 2016.   The Phase 1 clinical trial is currently estimated to cost a total of approximately $2,200,000, with such payments expected to be allocated approximately 60% for services provided by Theradex and approximately 40% for pass-through costs for clinical center laboratory costs and investigator costs over the life of the clinical trial. Total costs charged to operations through March 31, 2016 for services paid to or through Theradex pursuant to this arrangement, which were first incurred in 2013, aggregated $1,774,276, of which $113,551 and $350,601 were incurred during the three months ended March 31, 2016 and 2015, respectively, or approximately 43% and 69% of research and development costs for the three months ended March 31, 2016 and 2015, respectively. Costs pursuant to this agreement are included in research and development costs in the Companys condensed consolidated statements of operations.

Income Taxes   The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities.   The Company has elected to deduct research and development costs on a current basis for federal income tax purposes. For federal tax purposes, start-up and organization costs were deferred until January 1, 2008 at which time the Company began to amortize such costs over a 180-month period.   The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made.   The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Companys net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of March 31, 2016 and 2015 and does not anticipate any material amount of unrecognized tax benefits within the next 12 months.   The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is more-likely-than-not to be sustained by the taxing authority as of the reporting date. If the tax position is not considered more-likely-than-not to be sustained, then no benefits of the position are recognized. As of March 31, 2016, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense.

Stock-Based Compensation   The Company periodically issues common stock and stock options to officers, directors, Scientific Advisory Committee members and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each grant.   The Company accounts for stock-based payments to officers and directors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Companys financial statements over the vesting period of the awards. The Company accounts for stock-based payments to Scientific Advisory Committee members and consultants by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached or (b) at the date at which the necessary performance to earn the equity instruments is complete.   Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.   Stock options granted to members of the Companys Scientific Advisory Committee and to outside consultants are revalued each reporting period to determine the amount to be recorded as an expense in the respective period. As the stock options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the value on the date of vesting.   The fair value of common stock issued as stock-based compensation is determined by reference to the closing price of the Companys common stock on the date of issuance. The fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award. Estimated volatility is based on the historical volatility of the Companys common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market value of common stock is determined by reference to the quoted market price of the Companys common stock.   The Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development costs, as appropriate, in the Companys condensed consolidated statement of operations. The Company issues new shares of common stock to satisfy stock option exercises.

Comprehensive Income (Loss)   Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). The Company did not have any items of comprehensive income (loss) for the three months ended March 31, 2016 and 2015.

Earnings (Loss) Per Share   The Companys computation of earnings (loss) per share (EPS) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares, warrants and stock options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.   Net income (loss) attributable to common stockholders consists of net income or loss, as adjusted for preferred stock dividends declared, amortized or accumulated.   Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all preferred shares, warrants and stock options outstanding are anti-dilutive.   At March 31, 2016 and 2015, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">March 31,</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2015</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 64%; line-height: 115%">Series A Convertible Preferred Stock</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 15%; text-align: right; line-height: 115%">4,375,000</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 15%; text-align: right; line-height: 115%">2,187,500</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Common stock warrants</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2,928,800</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Common stock options</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">7,950,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">6,825,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Total</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">12,325,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">11,941,300</td> <td style="line-height: 115%"> </td></tr> </table>

Fair Value of Financial Instruments   The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required.   Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives.   Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges.   Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models.   The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end.   Money market funds are the only financial instrument that is measured and recorded at fair value on the Companys consolidated balance sheet on a recurring basis.   The carrying value of financial instruments (consisting of cash and accounts payable and accrued expenses) is considered to be representative of their respective fair values due to the short-term nature of those instruments.

Use of Estimates   The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements   In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. Based on the FASBs Exposure Draft Update issued on April 29, 2015, Revenue from Contracts With Customers (Topic 606): Deferral of the Effective Date, it is expected that ASU 2014-09 will now be effective for reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The adoption of ASU 2014-09 is not expected to have any impact on the Companys financial statement presentation or disclosures.   In August 2014, the FASB issued Accounting Standards Update No. 2014-15 (ASU 2014-15), Presentation of Financial Statements Going Concern (Subtopic 205-10). ASU 2014-15 provides guidance as to managements responsibility to evaluate whether there is substantial doubt about an entitys ability to continue as a going concern and to provide related footnote disclosures. In connection with preparing financial statements for each annual and interim reporting period, an entitys management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entitys ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). Managements evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued (or at the date that the financial statements are available to be issued when applicable). Substantial doubt about an entitys ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have any impact on the Companys financial statement presentation and disclosures.   In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The Company has not yet evaluated the impact of the adoption of ASU 2016-02 on the Companys financial statement presentation or disclosures.   Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Companys financial statement presentation or disclosures.

0.60 0.40 5. Money Market Funds   Money market funds at March 31, 2016 and December 31, 2015 consisted of investments in shares of Morgan Stanley New York Municipal Money Market Trust with a market value of $870,773 and $104,095, respectively.   The Morgan Stanley New York Municipal Money Market Trust is an open-end fund incorporated in the USA. The Funds objective is as high level of daily income exempt from federal and New York income tax as is consistent with stability of principal and liquidity. The Fund invests in high quality, short- term municipal obligations that pay interest exempt from federal and NY taxes.   The following table presents money market funds at their level within the fair value hierarchy at March 31, 2016 and December 31, 2015.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 1</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 2</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Level 3</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">March 31, 2016:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 44%; line-height: 115%">Money market funds</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%">870,773</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%">870,773</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">December 31, 2015:</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Money market funds</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">104,095</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">104,095</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td></tr> </table>

6. Related Party Transactions   The Company had advances from its Chairman and major stockholder, Dr. John Kovach, aggregating $92,717, which were non-interest bearing, due on demand, and included in current liabilities in the Companys consolidated balance sheets through December 31, 2014. Effective March 17, 2015, such advances were converted into 92,717 shares of the Companys common stock, reflecting an effective price of $1.00 per share. On the effective date of the transaction, the closing price of the Companys common stock was $0.25 per share.   Dr. Kovach was paid a salary of $15,000 for the three months ended March 31, 2016 and 2015, which amounts are included in general and administrative costs in the Companys condensed consolidated statements of operations.   Dr. Kovach is not involved in other business activities but could, in the future, become involved in other business opportunities that become available. Accordingly, Dr. Kovach may face a conflict in selecting between the Company and his other business interests. The Company has not yet formulated a policy for the resolution of such potential conflicts.   The Companys principal office facilities have been provided without charge by Dr. Kovach. Such costs were not material to the Companys consolidated financial statements and, accordingly, have not been reflected therein.   Legal and consulting fees charged to operations for services rendered by the Eric Forman Law Office were $12,000 for the three months ended March 31, 2016 and 2015. Eric J. Forman is the son-in-law of Gil Schwartzberg, a significant stockholder of and consultant to the Company.    Effective January 1, 2014, the Company entered into an Advisory Agreement with Dr. Kathleen P. Mullinix, a member of the Board of Directors of the Company, effective for an initial term of one year through December 31, 2014 to advise on business development matters. The Advisory Agreement provided for annual cash compensation of $25,000. The term of the Advisory Agreement is automatically extended for a term of one year annually unless a notice of intent to terminate is given by either party at least 90 days before the end of the applicable term. Accordingly, the Advisory Agreement was extended for additional terms of one year effective January 1, 2015 and 2016. The Company recognized a charge to operations of $6,250 as consulting and advisory fees pursuant to this Advisory Agreement during the three months ended March 31, 2016 and 2015, which were included in general and administrative costs in the Companys condensed consolidated statements of operations.   Stock-based compensation arrangements involving members of the Companys Board of Directors and affiliates are described at Note 7. Total stock-based compensation expense relating to directors, officers, affiliates and related parties was $0 and $74,901 for the three months ended March 31, 2016 and 2015, respectively.

7. Stock-Based Compensation   The Company issues common stock and stock options as incentive compensation to directors and as compensation for the services of independent contractors and consultants of the Company.   On June 20, 2007, the Board of Directors of the Company approved the 2007 Stock Compensation Plan (the 2007 Plan), which provides for the granting of awards, consisting of stock options, stock appreciation rights, performance shares, or restricted shares of common stock, to employees and independent contractors, for up to 2,500,000 shares of the Companys common stock, under terms and condition, as determined by the Companys Board of Directors. As of March 31, 2016, unexpired stock options for 550,000 shares were issued and outstanding under the 2007 Plan, and stock options for 1,950,000 were available for issuance under the 2007 Plan.   The fair value of each stock option awarded is estimated on the date of grant and subsequent measurement dates using the Black-Scholes option-pricing model. The expected dividend yield assumption is based on the Companys expectation of dividend payouts. The expected volatilities are based on historical volatility of the Companys stock. The risk-free interest rate is based on the U.S. treasury yield curve in effect as of the grant date. The expected life of the stock options is the average of the vesting term and the full contractual term of the stock options.   For stock options requiring an assessment of value during the three months ended March 31, 2016, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model with the following assumptions:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Risk-free interest rate</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0.74% to 1.23</td> <td style="line-height: 115%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 79%; line-height: 115%">Expected dividend yield</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 18%; text-align: right; line-height: 115%">0</td> <td style="width: 1%; line-height: 115%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Expected volatility</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">196.75</td> <td style="line-height: 115%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Expected life</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2.7 to 4.7 years</td> <td style="line-height: 115%"> </td></tr> </table>   For stock options requiring an assessment of value during the three months ended March 31, 2015, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model with the following assumptions:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; line-height: 115%">Risk-free interest rate</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 18%; text-align: right; line-height: 115%">1.33</td> <td style="width: 1%; line-height: 115%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Expected dividend yield</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0</td> <td style="line-height: 115%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Expected volatility</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">243</td> <td style="line-height: 115%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Expected life</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.7 to 4.5 years</td> <td style="line-height: 115%"> </td></tr> </table>   On January 28, 2014, the Company approved a second amendment to the Companys consulting agreement with Gil Schwartzberg, a significant stockholder of and consultant to the Company, dated September 12, 2007 to extend it for an additional four years to January 28, 2019 and granted to Mr. Schwartzberg stock options to purchase an additional aggregate of 4,000,000 shares of common stock, exercisable for a period of the earlier of five years from the grant date or the termination of the consulting agreement at $0.50 per share, with one-half of the stock options (2,000,000 shares) vesting immediately and one-half of the stock options (2,000,000 shares) vesting on January 28, 2015. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $596,400 ($0.15 per share) on January 28, 2014, of which $298,200 was attributed to the stock options that were fully vested on January 28, 2014 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from January 28, 2014 through January 28, 2015. During the three months ended March 31, 2015, the Company recorded a charge to operations of $74,901 with respect to these stock options.    On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. (NDA) for consultation and advice in the field of oncology research and drug development. As part of the agreement, NDA also agreed to cause its president, Dr. Daniel D. Von Hoff, M.D., to become a member of the Companys Scientific Advisory Committee. In connection with this agreement, NDA was granted stock options to purchase 100,000 shares of the Companys common stock, vesting 25,000 shares on June 24, 2014, and thereafter 25,000 shares annually on June 24, 2015, 2016 and 2017, exercisable for a period of five years from the date of grant at $0.13 per share, which was the fair market value of the Companys common stock on the grant date. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $12,960 ($0.13 per share), and is being charged to operations ratably from December 24, 2013 through June 24,2017. During the three months ended March 31, 2016 and 2015, the Company recorded a (credit) charge to operations of $(10,796) and $2,316, respectively, with respect to these stock options.   On October 7, 2014, the Company entered into an Advisory Agreement with Andrew Robell for consultation and advice with respect to identifying and assessing potential licensing and strategic opportunities through September 30, 2016. In connection with the agreement, the Company granted stock options to Mr. Robell to purchase 200,000 shares of the Companys common stock, vesting 100,000 shares on October 7, 2014 and 100,000 shares on October 7, 2015, exercisable for a period of five years from the date of grant at $0.50 per share. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $20,000 ($0.10 per share), of which $10,000 is attributed to the stock options fully-vested on October 7, 2014 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from October 7, 2014 through October 7, 2015. During the three months ended March 31, 2015, the Company recorded a charge to operations of $6,777 with respect to these stock options.   On October 7, 2014, the Company entered into an agreement with ProActive Capital Resources Group LLC (ProActive) for strategic advisory, investor relations and public relations services through October 6, 2015. In connection with the agreement, the Company agreed to pay ProActive a monthly fee of $1,500 in cash and agreed to issue to ProActive 250,000 shares of the Companys common stock, vesting 125,000 shares upon execution of the agreement on October 7, 2014 and 125,000 shares six months thereafter on April 7, 2015. Additionally, the Company issued a stock option in the form of a warrant to ProActive to purchase 500,000 shares of the Companys common stock, vesting upon execution of the agreement on October 7, 2014, and exercisable for a period of one year from the date of grant at $0.25 per share. The fair value of the warrant, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $33,000 ($0.066 per share). The Company inadvertently neglected to timely record a charge to operations in 2014 of $45,500 with respect to this transaction, as well as to record a portion of the fair value of the remaining unvested 125,000 shares in 2014 (which had a fair value on the grant date of $12,500). The Company recorded a charge to operations for the aggregate fair value of these securities of $76,750 during the three months ended June 30, 2015. Management performed an evaluation with respect to this matter and determined that this correction was not qualitatively or quantitatively material to the Companys financial statements for the years ended December 31, 2014 or 2015, and thus determined that no restatement of such prior periods was necessary or appropriate under the circumstances.   Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks LLC (BioPharmaWorks), pursuant to which the Company engaged BioPharmaWorks to perform certain services for the Company as described at Note 8. In connection with the Collaboration Agreement, the Company agreed to issue to BioPharmaWorks 1,000,000 fully-vested shares of the Companys common stock, valued at $260,000, based upon the closing price of the Companys common stock of $0.26 per share, on September 14, 2015. Additionally, the Company issued to BioPharmaWorks two options in the form of warrants to purchase 1,000,000 shares (500,000 shares per warrant) of the Companys common stock. The first warrant will vest on September 14, 2016, and is exercisable for a period of five years from the date of grant at $1.00 per share. The second warrant will vest on September 14, 2017, and is exercisable for a period of five years from the date of grant at $2.00 per share. The fair value of the first and second warrants, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $128,400 ($0.2568 per share) and $127,850 ($0.2557 per share), respectively. During the three months ended March 31, 2016, the Company recorded a credit to operations of $(20,733) with respect to these common shares and warrants.    On November 28, 2015, the Company entered into a two-year advisory agreement with Dr. Fritz Henn, M.D., Ph.D., for consultation and advice on the development of certain of the Companys products for clinical neurological and neuropsychiatric applications. Dr. Henn is an internationally recognized investigative neuroscientist and psychiatrist. In connection with the advisory agreement, and as sole compensation, Dr. Henn was granted stock options to purchase 200,000 shares of the Companys common stock, with 100,000 shares vesting on November 28, 2015, and 100,000 shares vesting on November 28, 2016. The stock options are exercisable for a period of five years from the grant date at $0.50 per share. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $103,360 ($0.5168 per share), of which $51,680 is attributed to the options fully-vested on November 28, 2015 and was therefore was charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from November 28, 2015 through November 28, 2016. During the three months ended March 31, 2016, the Company recorded a charge to operations of $1,159 with respect to these stock options.   Total stock-based compensation expense (credit) was $(30,370) and $83,994, respectively, for the three months ended March 31, 2016 and 2015. The credit for the vested portion of the fair value of common stock options and warrants of $(30,370) for the three months ended March 31, 2016 was primarily attributable to a decline in the Companys stock price from December 31, 2015 through March 31, 2016.   A summary of stock option activity during the three months ended March 31, 2016 is presented in the tables below.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Weighted</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Average</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Weighted</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Remaining</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Number</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Average</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Contractual</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Of</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Exercise</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Life</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Shares</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Price</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">(in Years)</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 115%">Options outstanding at December 31, 2015</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 14%; text-align: right; line-height: 115%">7,950,000</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 14%; text-align: right; line-height: 115%">0.697</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 14%; text-align: right; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Granted</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Exercised</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Expired</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Options outstanding at March 31, 2016</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">7,950,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">0.697</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">2.69</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Options exercisable at December 31, 2015</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">6,800,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">0.586</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Options exercisable at March 31, 2016</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">6,800,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">0.586</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">2.40</td> <td style="line-height: 115%"> </td></tr> </table>   Total deferred compensation expense for the outstanding value of unvested stock options was approximately $74,000 at March 31, 2016, which is being recognized subsequent to March 31, 2016 over a weighted-average period of approximately twelve months.   The exercise prices of common stock options outstanding and exercisable are as follows at March 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Options</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Options</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center; line-height: 115%">Exercise</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Outstanding</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%">Exercisable</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Prices</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">(Shares)</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">(Shares)</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 32%; text-align: right; line-height: 115%">0.130</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 2%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 29%; text-align: right; line-height: 115%">100,000</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 2%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 29%; text-align: right; line-height: 115%">50,000</td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.250</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">500,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">500,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.500</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4,400,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">4,300,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.650</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">700,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">700,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">0.980</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">250,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">250,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">1.000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,500,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">1,000,000</td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">$</td> <td style="text-align: right; line-height: 115%">2.000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">500,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">7,950,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">6,800,000</td> <td style="line-height: 115%"> </td></tr> </table>   Based on a fair market value of $0.12 per share on March 31, 2016, there were no exercisable but unexercised in-the-money stock options outstanding at March 31, 2016. Such stock options had no intrinsic value at such date.   The intrinsic value of exercisable but unexercised in-the-money stock options at December 31, 2015 was approximately $31,300, based on a fair market value of $0.296 per share on December 31, 2015.   Outstanding options to acquire 1,150,000 shares of the Companys common stock had not vested at March 31, 2016.   The Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.

6250

1500

4000

25000

10000

6250

30000

2500000

0.25

0.375

0.50

0.75

1.00

10.00

1.00

10.00

0.80

175000

1750000

-1750000

9. Subsequent Events   The Company performed an evaluation of subsequent events through the date of filing of these financial statements with the SEC, noting no items requiring disclosure.

1950000

125000

For stock options requiring an assessment of value during the three months ended March 31, 2016, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model with the following assumptions:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Risk-free interest rate</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0.74% to 1.23</td> <td style="line-height: 115%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 79%; line-height: 115%">Expected dividend yield</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 18%; text-align: right; line-height: 115%">0</td> <td style="width: 1%; line-height: 115%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Expected volatility</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">196.75</td> <td style="line-height: 115%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Expected life</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">2.7 to 4.7 years</td> <td style="line-height: 115%"> </td></tr> </table>   For stock options requiring an assessment of value during the three months ended March 31, 2015, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model with the following assumptions:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; line-height: 115%">Risk-free interest rate</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 18%; text-align: right; line-height: 115%">1.33</td> <td style="width: 1%; line-height: 115%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Expected dividend yield</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">0</td> <td style="line-height: 115%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Expected volatility</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">243</td> <td style="line-height: 115%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Expected life</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">3.7 to 4.5 years</td> <td style="line-height: 115%"> </td></tr> </table>

104095

870773

104095

870773

25281

99386

140101

44411

34016

33000

128400

127850

103360

-416543

-957919

-416543

6250

81151

116633 353037

315000

4. Stockholders Equity   Preferred Stock   The Company has authorized a total of 10,000,000 shares of preferred stock, par value $0.001 per share. On March 17, 2015, the Company filed a Certificate of Designations, Preferences, Rights and Limitations (the Certificate of Designations) of its Series A Convertible Preferred Stock with the Delaware Secretary of State to amend the Companys certificate of incorporation. The number of shares designated as Series A Convertible Preferred Stock was 175,000 (which are not subject to increase without the written consent of a majority of the holders of the Series A Convertible Preferred Stock or as otherwise set forth in the Certificate of Designations). Effective January 28, 2016, the Series A Convertible Preferred Stock Certificate of Designations was amended to increase the number of authorized shares of Series A Convertible Preferred Stock from 175,000 to 350,000. Accordingly, as of March 31, 2016, 9,650,000 shares of preferred stock were undesignated and may be issued with such rights and powers as the Board of Directors may designate   Effective March 17, 2015, the Company entered into a Securities Purchase Agreement with a current stockholder of the Company who owned 10.6% of the Companys issued and outstanding shares of common stock immediately prior to the financing transaction, pursuant to which such stockholder purchased 175,000 shares of the Companys non-voting Series A Convertible Preferred Stock (the Preferred Stock) at a price per share of $10.00, representing an aggregate purchase price of $1,750,000.   Effective January 28, 2016, the Company entered into a Securities Purchase Agreement with the holder of the Preferred Stock sold on March 17, 2015, pursuant to which the Company sold an additional 175,000 shares of Preferred Stock at a price per share of $10.00, representing an aggregate purchase price of $1,750,000, payable $583,333 on closing, $583,333 on or before March 4, 2016, and $583,334 on or before June 3, 2016. The first two installments were received during the three months ended March 31, 2016.   This class of Preferred Stock has a dividend per share equal to 1% of the annual net revenue of the Company divided by 175,000, until converted or redeemed. Based on the Companys net revenues for the year ended December 31, 2015 of $200,000, the Company recorded a dividend of $2,000 on the shares of Preferred Stock issued and outstanding at that time. The dividend has been presented as a current liability in the Companys condensed consolidated balance sheets as of March 31, 2016 and December 31, 2015.   Each share of Preferred Stock may be converted, at the option of the holder, into 12.5 shares of common stock (subject to customary anti-dilution provisions) and the Preferred Stock is subject to mandatory conversion at the conversion rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $21,875,000. The Preferred Stock has a liquidation preference based on its assumed conversion into shares of common stock.   If fully converted, the Preferred Stock sold in the March 17, 2015 closing would convert into 2,187,500 shares of common stock, representing an effective price per share of common stock of $0.80. On March 17, 2015, the closing price of the Companys common stock was $0.25 per share. If fully converted, the Preferred Stock sold in the January 21, 2016 closing would also convert into 2,187,500 shares of common stock, representing an effective price per share of common stock of $0.80. On January 21, 2016, the closing price of the Companys common stock was $0.22 per share. The Company has the right to redeem the Preferred Stock up to the fifth anniversary of the respective closing dates at a price per share equal to $50.00. The Preferred Stock has no right to cash, except for the payment of the aforementioned dividend when the Company generates revenues, and does not have any registration rights.   Based on the attributes of the Preferred Stock described above, the Company has determined to account for the Preferred Stock as a permanent component of stockholders equity. Legal costs of $12,608 incurred with respect to the issuance of the Preferred Stock on March 17, 2015 were charged directly to additional paid-in capital. No costs were incurred with respect to the issuance of the Preferred Stock on January 21, 2016.   Common Stock   Effective March 17, 2015, the Companys Chairman and major stockholder converted advances due to him aggregating $92,717 into 92,717 shares of the Companys common stock, reflecting an effective price of $1.00 per share. On the effective date of the transaction, the closing price of the Companys common stock was $0.25 per share. The Company accounted for this transaction as a capital transaction.   See Note 7 for information with respect to the issuance of common stock in connection with various stock-based compensation arrangements.   Common Stock Warrants   On March 6, 2015, the Companys Board of Directors extended to April 15, 2015 the outstanding warrants to acquire 2,928,800 shares of the Companys common stock, which were then currently scheduled to expire on March 31, 2015, and discounted the cash exercise prices of the warrants by 50%. Warrants so extended and discounted consisted of 1,075,000 warrants currently exercisable at $0.75 per share and 1,853,800 warrants currently exercisable at $0.50 per share. The difference in the fair value of the warrants immediately before and after the grant of the extensions, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $34,016 (average of $0.01 per share), and such amount was charged to operations on March 6, 2015. The fair value of the warrant extensions was calculated using the following input variables: stock price - $0.30 per share; exercise price - $0.50 and $0.75 per share; expected life 25 to 40 days; expected volatility 199%; expected dividend yield - 0%; risk-free interest rate 0.01%. The difference in the fair value of the warrants immediately before and after the grant of the discount, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $171,757 (an average of $0.06 per share), and such amount was charged to operations on March 6, 2015. The fair value of the warrant discount was calculated using the following input variables: stock price - $0.30 per share; exercise price - $0.50 and $0.75 per share to $0.25 and $0.375 per share, respectively; expected life 15 days (the period during which the discount was available); expected volatility 199%; expected dividend yield - 0%; risk-free interest rate 0.01%.  As a result of the March 6, 2015 warrant extension and discount offers, warrants to acquire 1,050,000 shares of the Companys common stock were exercised in April 2015 (including warrants to acquire 500,000 shares of common stock by Dr. Debbie Schwartzberg, an affiliate of the Company, and 300,000 shares of common stock by Philip F. Palmedo, a director of the Company) at exercise prices ranging from $0.25 to $0.375 per share. The exercise of the warrants generated aggregate net proceeds to the Company of $315,000 (average exercise price of $0.30 per share).   As of December 31, 2015 and March 31, 2016, there were no warrants outstanding to purchase common stock.

92717

9650000 0.01 12.5 0.25 0.25 0.25 0.22

15000

74000

31300

7950000

6800000

92717

8. Commitments and Contingencies   The Company is not currently subject to any pending or threatened legal actions or claims.   Significant agreements and contracts are summarized as follows:   On September 21, 2012, the Company entered into a work order agreement with Theradex, the CRO responsible for the clinical development of the Companys lead compound, LB-100, to manage and administer the Phase 1 clinical trial of LB-100. The Phase 1 clinical trial of LB-100, which began during April 2013 with the entry of patients into the clinical trial, is being carried out by nationally recognized comprehensive cancer centers, and is estimated to be completed by May 31, 2016. The Phase 1 clinical trial is currently estimated to cost a total of approximately $2,200,000, with such payments expected to be allocated approximately 60% for services provided by Theradex and approximately 40% for pass-through costs for clinical center laboratory costs and investigator costs over the life of the clinical trial. Total costs charged to operations through March 31, 2016 for services paid to or through Theradex pursuant to this arrangement, which were first incurred in 2013, aggregated $1,774,276, of which $113,551 and $350,601 were incurred during the three months ended March 31, 2016 and 2015, respectively. Costs pursuant to this agreement are included in research and development costs in the Companys condensed consolidated statements of operations.   On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. (NDA) for consultation and advice in the field of oncology research and drug development. As part of the agreement, NDA also agreed to cause its president, Dr. Daniel D. Von Hoff, M.D., to become a member of the Companys Scientific Advisory Committee. The term of the agreement was for one year and provided for a quarterly cash fee of $4,000. The agreement was automatically renewed on its anniversary date for an additional one-year term. Consulting and advisory fees charged to operations pursuant to this agreement were $4,000 during the three months ended March 31, 2016 and 2015.   Effective January 1, 2014, the Company entered into an Advisory Agreement with Dr. Kathleen P. Mullinix, a member of the Board of Directors of the Company, effective for an initial term of one year through December 31, 2014 to advise on business development matters. The Advisory Agreement provided for annual cash compensation of $25,000. The term of the Advisory Agreement was automatically extended for a term of one year annually unless a notice of intent to terminate was given by either party at least 90 days before the end of the applicable term. Accordingly, the Advisory Agreement was extended for additional terms of one year effective January 1, 2015 and 2016. The Company recognized a charge to operations of $6,250 as consulting and advisory fees pursuant to this Advisory Agreement during the three months ended March 31, 2016 and 2015.   On October 7, 2014, the Company entered into an agreement with ProActive Capital Resources Group LLC for strategic advisory, investor relations and public relations services through October 6, 2015. Among other things, the agreement provided for compensation in the form of a monthly fee of $1,500 in cash. Fees charged to operations pursuant to this agreement was $4,500 during the three months ended March 31, 2015.   Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged BioPharmaWorks to perform certain services for the Company. Those services include, among other things: (a) assisting the Company to (i) commercialize its products and strengthen its patent portfolio, (ii) identify large pharmaceutical companies with potential interest in the Companys product pipeline, and (iii) prepare and deliver presentations concerning the Companys products; (b) at the request of the Board of Directors, serving as backup management for up to three months should the Companys Chief Executive Officer and scientific leader be temporarily unable to carry out his duties; (c) being available for consultation in drug discovery and development; and (d) identifying providers and overseeing tasks relating to clinical use and commercialization of new compounds. BioPharmaWorks was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience. The Collaboration Agreement is for an initial term of two years and automatically renews for subsequent annual periods unless terminated by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the Company agreed to pay BioPharmaWorks a monthly fee of $10,000, subject to the right of the Company to pay a negotiated hourly rate in lieu of the monthly payment, and agreed to issue to BioPharmaWorks certain equity-based compensation as described at Note 7. Fees charged to operations pursuant to this Collaboration Agreement was $30,000 during the three months ended March 31, 2016.    The following table sets forth the Companys principal cash obligations and commitments for the next five fiscal years as of March 31, 2016 aggregating $494,914, of which $75,259 is included in current liabilities in the Companys condensed consolidated balance sheet at March 31, 2016. Amounts included in the 2016 column represent amounts due at March 31, 2016 for the remainder of the 2016 fiscal year ending December 31, 2016.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="18" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Payments Due By Year</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">Total</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2016</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2017</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2018</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2019</td> <td style="text-align: center; line-height: 115%"> </td> <td style="text-align: center; line-height: 115%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">2020</td> <td style="text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td colspan="2" style="line-height: 115%"> </td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 40%; line-height: 115%">Research and development contracts</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 7%; text-align: right; line-height: 115%">41,004</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 7%; text-align: right; line-height: 115%">41,004</td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 7%; text-align: right; line-height: 115%"></td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 7%; text-align: right; line-height: 115%"></td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 7%; text-align: right; line-height: 115%"></td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%">$</td> <td style="width: 7%; text-align: right; line-height: 115%"></td> <td style="width: 1%; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Clinical trial agreements</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">256,910</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%">256,910</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 115%">Consulting agreements</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">197,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">107,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%">90,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 115%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Total</td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">494,914</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">404,914</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%">90,000</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td> <td style="line-height: 115%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 115%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"></td> <td style="line-height: 115%"> </td></tr> </table>

LIXT

50.00

1750000

970159 0.43 0.69

2187500

500000 300000

0.50

0.75

0.50

0.75

0.25

0.375

25000

0.0123

0.0074

76750

500000 1000000 500000 500000

12500

494914 75259 10.00 10.00 1774276 113551 350601

416554

752157

264497

505514

152057

246643

-416554

-752157

47875814

45498550

-0.01

-0.02

-75673

-12575

766678 1103068

74105

95690

LIXTE BIOTECHNOLOGY HOLDINGS, INC. 0.106 2015-01-28 2016-11-28 2928800 1050000 47875814 Q1

597975

1224703

597975

1224703

60922

54146

207677 200398

285642

192615

124566 107212

159076

83403

597975

1224703

-18572269

-18988812

17129815

17099445

4787

1750000

3500000

88162 47854

47875814

350000

175000

47875814

312333

1032088

4787

17129815

-18572269

3500000

1750000

4787

17099445

-18988812

-583332

1750000

200000

50000

150000

200000

0.10 0.10 0.15

P2Y8M9D

2016 200000

2000

185392 183063

200000

-416543

-957919

-30370 2316 81678 -200000

3000000

183063

1. Organization, Business and Basis of Presentation   Organization and Business   Lixte Biotechnology Holdings, Inc., a Delaware corporation (Holdings), including its wholly-owned Delaware subsidiary, Lixte Biotechnology, Inc. (Lixte) (collectively, the Company), is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Companys product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases.   The Companys activities are subject to significant risks and uncertainties, including the need for additional capital, as described below. The Company has not yet commenced any sustainable revenue-generating operations, does not have any positive cash flows from operations, and is dependent on equity capital to fund its operating requirements.   The Companys common stock is traded on the OTCQB operated by the OTC Markets under the symbol LIXT.   Basis of Presentation   The condensed consolidated financial statements of the Company at March 31, 2016, and for the three months ended March 31, 2016 and 2015, are unaudited. In the opinion of management of the Company, all adjustments (including normal recurring adjustments) have been made that are necessary to present fairly the financial position of the Company as of March 31, 2016, and the results of its operations for the three months ended March 31, 2016 and 2015, and its cash flows for the three months ended March 31, 2016 and 2015. Operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal year. The consolidated balance sheet at December 31, 2015 has been derived from the Companys audited financial statements at such date.   The statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the SEC). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the financial statements and other information included in the Companys Annual Report on Form 10-K for the fiscal year ended December 31, 2015, as filed with the SEC.   Going Concern   The Companys condensed consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any sustainable revenues from operations to date, and does not expect to do so in the foreseeable future. The Company has experienced recurring operating losses and negative operating cash flows since inception, and has financed its working capital requirements during this period primarily through the recurring sale of its equity securities and the exercise of outstanding warrants. As a result, management has concluded that there is substantial doubt about the Companys ability to continue as a going concern, and the Companys independent registered public accounting firm, in their report on the Companys consolidated financial statements for the year ended December 31, 2015, has expressed substantial doubt about the Companys ability to continue as a going concern.    The Companys ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research and development activities and to ultimately achieve sustainable operating revenues and profits. The Companys consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.   Because the Company is currently engaged in research at a relatively early stage, it will likely take a significant amount of time to develop any product or intellectual property capable of generating sustainable revenues. Accordingly, the Companys business is unlikely to generate any sustainable operating revenues in the next several years, and may never do so. In addition, to the extent that the Company is able to generate revenues through licensing its technologies or through product sales, there can be no assurance that the Company will be able to achieve positive earnings and operating cash flows.   At March 31, 2016, the Company had cash and money market funds aggregating $970,159. In January 2016, the Company entered into an agreement to sell additional shares of preferred stock for aggregate cash proceeds of $1,750,000 to be received by June 3, 2016, in three approximately equal installments. As of March 31, 2016, the Company had received two such installments totaling $1,166,668, with the third installment scheduled to be received by June 3, 2016. The Company also expects to receive a refund of an advance made through Theradex of $181,510 upon the completion of the current clinical trial. Consequently, the Company believes that it will have sufficient funds to complete the Phase 1 clinical trial of its lead anti-cancer compound LB-100 and to conduct a Phase 1b/2 clinical trial of LB-100 in the hematologic disorder known as myelodysplastic syndrome, as well as to fund the Companys ongoing operating expenses, including maintaining its patent portfolio, through mid-2017.   The amount and timing of future cash requirements will depend on the pace and design of the Companys clinical trial program. The Company currently plans to attempt to raise an additional approximately $3,000,000 of capital in the second half of 2016, likely in the form of equity, to also conduct a Phase 1b/2 clinical trial of LB-100 in combination with a platinum compound in platinum-resistant ovarian cancer and to extend the Companys pre-clinical research on compounds in its pipeline.   As market conditions present uncertainty as to the Companys ability to secure additional funds, there can be no assurances that the Company will be able to secure additional financing on acceptable terms, or at all, as and when necessary to continue to conduct operations. If cash resources are insufficient to satisfy the Companys ongoing cash requirements, the Company would be required to scale back or discontinue its technology and product development programs and/or clinical trials, or obtain funds, if available (although there can be no certainty), through strategic alliances that may require the Company to relinquish rights to certain of its compounds, or to discontinue its operations entirely.

Accounting for Preferred Stock   The Company accounts for preferred stock as either equity or debt, depending on the specific characteristics of the security issued. The Series A Convertible Preferred Stock issued by the Company in January 2016 and March 2015 has been classified in stockholders equity, as described at Note 4.

Revenue Recognition   The Company recognizes revenue when all four of the following criteria are met: (i) persuasive evidence that an arrangement exists; (ii) delivery of the products and/or services has occurred; (iii) the fees earned can be readily determined; and (iv) collectability of the fees is reasonably assured.   Revenues from milestone payments under license agreements are recognized when earned and the Company has no further performance obligations thereunder.

2200000 3. License Agreement   Effective December 25, 2015, the Company entered into a License Agreement (the TMU License Agreement) with Taipei Medical University (TMU), pursuant to which the Company granted to TMU an exclusive license of its lead anti-cancer compound, LB-100, for treatment of hepatocellular carcinoma (HCC) in Asia. Under the TMU License Agreement, TMU will determine the effectiveness of LB-100 against HCC in clinical trials conducted in accordance with both Taiwan and United States regulatory requirements.   Under the TMU License Agreement, TMU is obligated to make non-refundable milestone payments to the Company of $200,000 within ninety days from the effective date of December 25, 2015, $50,000 upon the completion of the first Phase 1b/2 clinical trial, $150,000 upon the completion of the first Phase 3 clinical trial, and $200,000 upon the first filing of a New Drug Application (NDA) with the FDA or a comparable non-United States regulatory authority. During the term of the TMU License Agreement, TMU will also pay earned royalties of 10% on cumulative net sales, and 10% to 15% on non-sale based sub-license income. A Phase 1b/2 clinical trial of LB-100 plus doxorubicin, to be managed and funded by TMU, is expected to commence during the third quarter of 2016.   The Company did not have any further performance obligations under the TMU License Agreement on the December 25, 2015 effective date. Accordingly, as the $200,000 licensing fee was fully earned on the December 25, 2015 effective date, the Company recorded such amount as licensing fee revenue at December 31, 2015. The Company received the $200,000 milestone payment on March 18, 2016.

583333

583334

583333

583332

350000

175000

350000

175000

17500000

8750000

4375000

2187500

1166668 1166668

-30370

-7279 -55654

-6776

-401

-17354 86038

-325885

-538634

171757

-766678

-1103068

12608

1166668

1737392

1750000

Patent Costs   Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Companys research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred. Patent costs were $101,956 and $127,481 for the three months ended March 31, 2016 and 2015, respectively. Patent costs are included in research and development costs in the Companys condensed consolidated statements of operations.

1166668

0001335105

175000

200000

2000

12000

51680

1150000

1500

175000 30000 4500 181510

EX-101.SCH 5 lixt-20160331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statement of Stockholders’ Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Organization, Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - License Agreement link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Money Market Funds link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Money Market Funds (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Organization, Business and Basis of Presentation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - License Agreement (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Money Market Funds (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Money Market Funds - Fair Value Assets Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of each Option Award Estimated Assumption (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Stock-Based Compensation - Exercise Prices of Common Stock Options Outstanding and Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Commitments and Contingencies - Schedule of Principal Cash Obligations and Commitments (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 lixt-20160331_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 lixt-20160331_def.xml XBRL DEFINITION FILE EX-101.LAB 8 lixt-20160331_lab.xml XBRL LABEL FILE Common Stock Options [Member] Major Types of Debt and Equity Securities [Axis] Warrant [Member] Equity Components [Axis] Exercise Price One [Member] Award Type [Axis] Exercise Price Two [Member] Money Market Funds [Member] Restricted Cash and Cash Equivalents [Axis] Level 1 [Member] Fair Value, Hierarchy [Axis] Level 2 [Member] Level 3 [Member] Theradex Systems, Inc [Member] Agreement [Axis] Related Party [Axis] Warrants One [Member] Warrants Two [Member] Warrants Three [Member] Warrants Four [Member] Warrants Extensions One [Member] Minimum [Member] Range [Axis] Maximum [Member] Warrants Extensions Two [Member] Warrant Extension [Member] Consulting Arrangements [Member] Plan Name [Axis] Mr.Schwartzberg [Member] Title of Individual [Axis] Dr. Kathleen P. Mullinix [Member] Immediate Vesting [Member] Quarterly Vesting Thereafter [Member] NDA Agreement [Member] Vesting On June 24, 2016 [Member] Vesting On June 24, 2017 [Member] Exercise Price Three [Member] Exercise Price Range [Axis] Exercise Price Four [Member] Exercise Price Five [Member] Exercise Price Six [Member] Payments Due By 2019 [Member] Payments Due By Year [Axis] Payments Due By 2020 [Member] Payments Due By 2016 [Member] Payments Due By 2017 [Member] Payments Due By 2018 [Member] Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Warrants Five [Member] Warrants Six [Member] Warrant Seven [Member] Warrants Extensions Three [Member] Eric Forman Law Office [Member] Phase 1 Clinical [Member] Dr. Kovach [Member] September 30, 2016 [Member] Report Date [Axis] Common Stock Warrants [Member] 2007 Stock Compensation Plan [Member] Andrew Robell [Member] Advisory Agreement [Member] Series A Convertible Preferred Stock [Member] Non-Voting Series A Convertible Preferred Stock [Member' Class of Stock [Axis] Preferred Stock [Member] Warrant Eight [Member] Warrants Extensions Four [Member] Warrants Extensions Five [Member] Minimum One [Member] Maximum One [Member] Warrants Extensions Six [Member] Francis Johnson [Member] Chem-Master International, Inc [Member] Legal Entity [Axis] Vested [Member] Agreemnt With ProActive Capital Resources Group LLC [Member] Type of Arrangement and Non-arrangement Transactions [Axis] NDA Consulting Corp [Member] Warrants 0.50 Price Per Share [Member] Warrants 0.75 Price Per Share [Member] Minimum Two [Member] Maximum Two [Member] Eric Forman [Member] Related Party Transaction [Axis] Dr Kathleen P Mullinix [Member] Chairman and Major Stockholder [Member] Subsidiary, Sale of Stock [Axis] December 31, 2015 [Member] Collaboration Agreement Bio PharmaWorks LLC [Member] First Warrant [Member] September 14, 2016 [Member] Second Warrant [Member] September 14, 2017 [Member] Stock Award Plan [Axis] Exercise Price Seven [Member] First Quarter of 2016 [Member] May 31, 2016 [Member] June 30, 2016 [Member] Second Half Of 2016 [Member] 2016 [Member] License Agreement [Member] Taipei Medical University [Member] First Phase 1b/2 Clinical Trial [Member] Scenario [Axis] First Phase 3 Clinical Trial [Member] First Filing of New Drug Application [Member] Cumulative Net Sales [Member] Income Statement Location [Axis] Non-Sale Based Sub-License Income [Member] January 28, 2016 [Member] Dr. Debbie Schwartzberg [Member] Philip F. Palmedo [Member] Securities Purchase Agreement [Member] June 3, 2016 [Member] Advisory Agreement With Dr. Fritz Henn [Member] Gil Schwartzberg [Member] November 28, 2016 [Member] Series A Convertible Preferred Stock Subscription Receivable [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current assets: Cash Money market funds License fee receivable Advances on research and development contract services, including $183,063 and $185,392 made to or through Theradex at March 31, 2016 and December 31, 2015, respectively Prepaid expenses and other current assets Total current assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued expenses Research and development contract liabilities, including $47,854 and $88,162 to Theradex at March 31, 2016 and December 31, 2015, respectively Dividend payable on Series A Convertible Preferred Stock Total current liabilities Commitments and contingencies Stockholders' equity: Series A Convertible Preferred Stock Common stock, $0.0001 par value; authorized – 100,000,000 shares; issued and outstanding – 47,875,814 shares at March 31, 2016 and December 31, 2015 Additional paid-in capital Subscription receivable for Series A Convertible Preferred Stock Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Statement [Table] Statement [Line Items] Advances on research and development contract services, from Theradex Research and development contract liabilities, Theradex Preferred stock, par value Preferred stock, stated value Preferred stock, per share redemption price Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Preferred stock, aggregate redemption value Preferred stock, issuable upon conversion Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Licensing revenues Costs and expenses: General and administrative costs, including $6,250 and $81,151 to related parties for the three months ended March 31, 2016 and 2015, respectively Research and development costs, including $116,633 and $353,037 to Theradex for the three months ended March 31, 2016 and 2015, respectively Total costs and expenses Loss from operations Interest income Fair value of warrant extensions Fair value of warrant discount Net loss Dividend on Series A Convertible Preferred Stock Net loss attributable to common stockholders Net loss per common share – basic and diluted Weighted average common shares outstanding – basic and diluted General and administrative costs, to related parties Research and development costs, to Theradex Balance EX-101.PRE 9 lixt-20160331_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2016	Apr. 29, 2016
Document And Entity Information
Entity Registrant Name	LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Entity Central Index Key	0001335105
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		47,875,814
Trading Symbol	LIXT
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2016

XML 11 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash	$ 99,386	$ 25,281
Money market funds	$ 870,773	104,095
License fee receivable		200,000
Advances on research and development contract services, including $183,063 and $185,392 made to or through Theradex at March 31, 2016 and December 31, 2015, respectively	$ 200,398	207,677
Prepaid expenses and other current assets	54,146	60,922
Total current assets	1,224,703	597,975
Total assets	1,224,703	597,975
Current liabilities:
Accounts payable and accrued expenses	83,403	159,076
Research and development contract liabilities, including $47,854 and $88,162 to Theradex at March 31, 2016 and December 31, 2015, respectively	107,212	124,566
Dividend payable on Series A Convertible Preferred Stock	2,000	2,000
Total current liabilities	$ 192,615	$ 285,642
Commitments and contingencies
Stockholders' equity:
Series A Convertible Preferred Stock	$ 3,500,000	$ 1,750,000
Common stock, $0.0001 par value; authorized – 100,000,000 shares; issued and outstanding – 47,875,814 shares at March 31, 2016 and December 31, 2015	4,787	4,787
Additional paid-in capital	17,099,445	$ 17,129,815
Subscription receivable for Series A Convertible Preferred Stock	(583,332)
Accumulated deficit	(18,988,812)	$ (18,572,269)
Total stockholders' equity	1,032,088	312,333
Total liabilities and stockholders' equity	$ 1,224,703	$ 597,975

XML 12 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Advances on research and development contract services, from Theradex	$ 183,063	$ 185,392
Research and development contract liabilities, Theradex	$ 47,854	$ 88,162
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	47,875,814	47,875,814
Common stock, shares outstanding	47,875,814	47,875,814
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, stated value	$ 10.00	10.00
Preferred stock, per share redemption price		$ 50.00
Preferred stock, shares authorized	350,000	175,000
Preferred stock, shares issued	350,000	175,000
Preferred stock, shares outstanding	350,000	175,000
Preferred stock, aggregate redemption value	$ 17,500,000	$ 8,750,000
Preferred stock, issuable upon conversion	4,375,000	2,187,500

XML 13 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Licensing revenues
Costs and expenses:
General and administrative costs, including $6,250 and $81,151 to related parties for the three months ended March 31, 2016 and 2015, respectively	$ 152,057	$ 246,643
Research and development costs, including $116,633 and $353,037 to Theradex for the three months ended March 31, 2016 and 2015, respectively	264,497	505,514
Total costs and expenses	416,554	752,157
Loss from operations	(416,554)	(752,157)
Interest income	$ 11	11
Fair value of warrant extensions		(34,016)
Fair value of warrant discount		(171,757)
Net loss	$ (416,543)	$ (957,919)
Dividend on Series A Convertible Preferred Stock
Net loss attributable to common stockholders	$ (416,543)	$ (957,919)
Net loss per common share – basic and diluted	$ (0.01)	$ (0.02)
Weighted average common shares outstanding – basic and diluted	47,875,814	45,498,550

XML 14 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
General and administrative costs, to related parties	$ 6,250	$ 81,151
Research and development costs, to Theradex	$ 116,633	$ 353,037

XML 15 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Stockholders’ Equity (Unaudited) - 3 months ended Mar. 31, 2016 - USD ($)	Series A Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Series A Convertible Preferred Stock Subscription Receivable [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2015	$ 1,750,000	$ 4,787	$ 17,129,815		$ (18,572,269)	$ 312,333
Balance, shares at Dec. 31, 2015	175,000	47,875,814
Sales of Series A Convertible Preferred Stock	$ 1,750,000			$ (1,750,000)
Sales of Series A Convertible Preferred Stock, shares	175,000
Subscription payments received from sale of Series A Convertible Preferred Stock				$ 1,166,668		$ 1,166,668
Stock-based compensation expense (credit)			$ (30,370)			(30,370)
Net loss					$ (416,543)	(416,543)
Balance at Mar. 31, 2016	$ 3,500,000	$ 4,787	$ 17,099,445	$ (583,332)	$ (18,988,812)	$ 1,032,088
Balance, shares at Mar. 31, 2016	350,000	47,875,814

XML 16 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net loss	$ (416,543)	$ (957,919)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense (credit) included in - General and administrative costs		81,678
Stock-based compensation expense (credit) included in - Research and development costs	$ (30,370)	2,316
Fair value of warrant - Extensions		34,016
Fair value of warrant - Discounts		$ 171,757
(Increase) decrease in -
Licensing fee receivable	$ 200,000
Advances on research and development contract services	7,279	$ 55,654
Prepaid expenses and other current assets	6,776	401
Increase (decrease) in -
Accounts payable and accrued expenses	(75,673)	(12,575)
Research and development contract liabilities	(17,354)	86,038
Net cash used in operating activities	(325,885)	(538,634)
Cash flows from investing activities:
(Increase) decrease in money market funds	(766,678)	(1,103,068)
Net cash used in investing activities	$ (766,678)	(1,103,068)
Cash flows from financing activities:
Proceeds from sale of Series A Convertible Preferred Stock		1,750,000
Cash payments made for costs incurred in connection with sale of Series A Convertible Preferred Stock		$ (12,608)
Cash received from sale of Series A Convertible Preferred Stock	$ 1,166,668
Net cash provided by financing activities	1,166,668	$ 1,737,392
Cash:
Net increase	74,105	95,690
Balance at beginning of period	25,281	44,411
Balance at end of period	$ 99,386	$ 140,101
Supplemental disclosures of cash flow information:
Interest
Income taxes
Non-cash financing activities:
Conversion of advances due to Chairman and major stockholder into common stock		$ 92,717
Sale of Series A Convertible Preferred Stock under stock subscription	$ 1,750,000

XML 17 R8.htm IDEA: XBRL DOCUMENT

Organization, Business and Basis of Presentation

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Organization, Business and Basis of Presentation

1. Organization, Business and Basis of Presentation

Organization and Business

The Company’s common stock is traded on the OTCQB operated by the OTC Markets under the symbol “LIXT”.

Basis of Presentation

Going Concern

XML 18 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Principles of Consolidation

Use of Estimates

Cash Concentrations

Research and Development

Patent Costs

Accounting for Preferred Stock

Concentration of Risk

Income Taxes

Stock-Based Compensation

Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.

Revenue Recognition

Revenues from milestone payments under license agreements are recognized when earned and the Company has no further performance obligations thereunder.

Comprehensive Income (Loss)

Earnings (Loss) Per Share

Net income (loss) attributable to common stockholders consists of net income or loss, as adjusted for preferred stock dividends declared, amortized or accumulated.

	March 31,
	2016		2015

Series A Convertible Preferred Stock		4,375,000		2,187,500
Common stock warrants		—		2,928,800
Common stock options		7,950,000		6,825,000
Total		12,325,000		11,941,300

Fair Value of Financial Instruments

Money market funds are the only financial instrument that is measured and recorded at fair value on the Company’s consolidated balance sheet on a recurring basis.

Recent Accounting Pronouncements

XML 19 R10.htm IDEA: XBRL DOCUMENT

License Agreement

3 Months Ended

Mar. 31, 2016

License Agreement

License Agreement

3. License Agreement

XML 20 R11.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

3 Months Ended

Mar. 31, 2016

Equity [Abstract]

Stockholders' Equity

4. Stockholders’ Equity

Preferred Stock

Common Stock

See Note 7 for information with respect to the issuance of common stock in connection with various stock-based compensation arrangements.

Common Stock Warrants

As of December 31, 2015 and March 31, 2016, there were no warrants outstanding to purchase common stock.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

XML 21 R12.htm IDEA: XBRL DOCUMENT

Money Market Funds

3 Months Ended

Mar. 31, 2016

Investments, Debt and Equity Securities [Abstract]

Money Market Funds

5. Money Market Funds

The following table presents money market funds at their level within the fair value hierarchy at March 31, 2016 and December 31, 2015.

	Total		Level 1		Level 2		Level 3

March 31, 2016:
Money market funds	$	870,773	$	870,773	$	—	$	—

December 31, 2015:
Money market funds	$	104,095	$	104,095	$	—	$	—

XML 22 R13.htm IDEA: XBRL DOCUMENT

Related Party Transactions

3 Months Ended

Mar. 31, 2016

Related Party Transactions

6. Related Party Transactions

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

XML 23 R14.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

3 Months Ended

Mar. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

7. Stock-Based Compensation

The Company issues common stock and stock options as incentive compensation to directors and as compensation for the services of independent contractors and consultants of the Company.

Risk-free interest rate	0.74% to 1.23	%
Expected dividend yield	0	%
Expected volatility	196.75	%
Expected life	2.7 to 4.7 years

Risk-free interest rate	1.33	%
Expected dividend yield	0	%
Expected volatility	243	%
Expected life	3.7 to 4.5 years

A summary of stock option activity during the three months ended March 31, 2016 is presented in the tables below.

					Weighted
					Average
			Weighted		Remaining
	Number		Average		Contractual
	Of		Exercise		Life
	Shares		Price		(in Years)

Options outstanding at December 31, 2015		7,950,000	$	0.697
Granted		—		—
Exercised		—		—
Expired		—		—
Options outstanding at March 31, 2016		7,950,000	$	0.697		2.69

Options exercisable at December 31, 2015		6,800,000	$	0.586
Options exercisable at March 31, 2016		6,800,000	$	0.586		2.40

The exercise prices of common stock options outstanding and exercisable are as follows at March 31, 2016:

		Options		Options
Exercise		Outstanding		Exercisable
Prices		(Shares)		(Shares)

$	0.130		100,000		50,000
$	0.250		500,000		500,000
$	0.500		4,400,000		4,300,000
$	0.650		700,000		700,000
$	0.980		250,000		250,000
$	1.000		1,500,000		1,000,000
$	2.000		500,000		—
			7,950,000		6,800,000

The intrinsic value of exercisable but unexercised in-the-money stock options at December 31, 2015 was approximately $31,300, based on a fair market value of $0.296 per share on December 31, 2015.

Outstanding options to acquire 1,150,000 shares of the Company’s common stock had not vested at March 31, 2016.

The Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.

XML 24 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

8. Commitments and Contingencies

The Company is not currently subject to any pending or threatened legal actions or claims.

Significant agreements and contracts are summarized as follows:

Effective January 1, 2014, the Company entered into an Advisory Agreement with Dr. Kathleen P. Mullinix, a member of the Board of Directors of the Company, effective for an initial term of one year through December 31, 2014 to advise on business development matters. The Advisory Agreement provided for annual cash compensation of $25,000. The term of the Advisory Agreement was automatically extended for a term of one year annually unless a notice of intent to terminate was given by either party at least 90 days before the end of the applicable term. Accordingly, the Advisory Agreement was extended for additional terms of one year effective January 1, 2015 and 2016. The Company recognized a charge to operations of $6,250 as consulting and advisory fees pursuant to this Advisory Agreement during the three months ended March 31, 2016 and 2015.

			Payments Due By Year
	Total		2016		2017		2018		2019		2020

Research and development contracts	$	41,004	$	41,004	$	—	$	—	$	—	$	—
Clinical trial agreements		256,910		256,910		—		—		—		—
Consulting agreements		197,000		107,000		90,000		—		—		—
Total	$	494,914	$	404,914	$	90,000	$	—	$	—	$	—

XML 25 R16.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Mar. 31, 2016

Subsequent Events [Abstract]

Subsequent Events

9. Subsequent Events

The Company performed an evaluation of subsequent events through the date of filing of these financial statements with the SEC, noting no items requiring disclosure.

XML 26 R17.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Principles of Consolidation

Principles of Consolidation

Use of Estimates

Use of Estimates

Cash Concentrations

Cash Concentrations

Research and Development

Research and Development

Patent Costs

Patent Costs

Accounting for Preferred Stock

Accounting for Preferred Stock

Concentration of Risk

Concentration of Risk

Income Taxes

Income Taxes

Stock-Based Compensation

Stock-Based Compensation

Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period.

Revenue Recognition

Revenue Recognition

Revenues from milestone payments under license agreements are recognized when earned and the Company has no further performance obligations thereunder.

Comprehensive Income (Loss)

Comprehensive Income (Loss)

Earnings (Loss) Per Share

Earnings (Loss) Per Share

Net income (loss) attributable to common stockholders consists of net income or loss, as adjusted for preferred stock dividends declared, amortized or accumulated.

	March 31,
	2016		2015

Series A Convertible Preferred Stock		4,375,000		2,187,500
Common stock warrants		—		2,928,800
Common stock options		7,950,000		6,825,000
Total		12,325,000		11,941,300

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Money market funds are the only financial instrument that is measured and recorded at fair value on the Company’s consolidated balance sheet on a recurring basis.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

XML 27 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share

	March 31,
	2016		2015

Series A Convertible Preferred Stock		4,375,000		2,187,500
Common stock warrants		—		2,928,800
Common stock options		7,950,000		6,825,000
Total		12,325,000		11,941,300

XML 28 R19.htm IDEA: XBRL DOCUMENT

Money Market Funds (Tables)

3 Months Ended

Mar. 31, 2016

Investments, Debt and Equity Securities [Abstract]

Fair Value Assets Measured on Recurring Basis

The following table presents money market funds at their level within the fair value hierarchy at March 31, 2016 and December 31, 2015.

	Total		Level 1		Level 2		Level 3

March 31, 2016:
Money market funds	$	870,773	$	870,773	$	—	$	—

December 31, 2015:
Money market funds	$	104,095	$	104,095	$	—	$	—

XML 29 R20.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Fair Value of Each Option Award Estimated Assumption

Risk-free interest rate	0.74% to 1.23	%
Expected dividend yield	0	%
Expected volatility	196.75	%
Expected life	2.7 to 4.7 years

Risk-free interest rate	1.33	%
Expected dividend yield	0	%
Expected volatility	243	%
Expected life	3.7 to 4.5 years

Summary of Stock Option Activity

A summary of stock option activity during the three months ended March 31, 2016 is presented in the tables below.

					Weighted
					Average
			Weighted		Remaining
	Number		Average		Contractual
	Of		Exercise		Life
	Shares		Price		(in Years)

Options outstanding at December 31, 2015		7,950,000	$	0.697
Granted		—		—
Exercised		—		—
Expired		—		—
Options outstanding at March 31, 2016		7,950,000	$	0.697		2.69

Options exercisable at December 31, 2015		6,800,000	$	0.586
Options exercisable at March 31, 2016		6,800,000	$	0.586		2.40

Exercise Prices of Common Stock Options Outstanding and Exercisable

The exercise prices of common stock options outstanding and exercisable are as follows at March 31, 2016:

		Options		Options
Exercise		Outstanding		Exercisable
Prices		(Shares)		(Shares)

$	0.130		100,000		50,000
$	0.250		500,000		500,000
$	0.500		4,400,000		4,300,000
$	0.650		700,000		700,000
$	0.980		250,000		250,000
$	1.000		1,500,000		1,000,000
$	2.000		500,000		—
			7,950,000		6,800,000

XML 30 R21.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Schedule of Principal Cash Obligations and Commitments

			Payments Due By Year
	Total		2016		2017		2018		2019		2020

Research and development contracts	$	41,004	$	41,004	$	—	$	—	$	—	$	—
Clinical trial agreements		256,910		256,910		—		—		—		—
Consulting agreements		197,000		107,000		90,000		—		—		—
Total	$	494,914	$	404,914	$	90,000	$	—	$	—	$	—

XML 31 R22.htm IDEA: XBRL DOCUMENT

Organization, Business and Basis of Presentation (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Jan. 31, 2016	Mar. 31, 2016
Organization And Business Operations [Line Items]
Cash and money market funds		$ 970,159
Proceeds from issuance of preferred stock	$ 1,750,000
Installments amount		1,166,668
Second Half Of 2016 [Member]
Organization And Business Operations [Line Items]
Additional capital		3,000,000
Theradex Systems, Inc [Member] \| Phase 1 Clinical [Member]
Organization And Business Operations [Line Items]
Advances on research and development contract services, to Theradex to be refunded		$ 181,510

XML 32 R23.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		39 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016
Patent costs	$ 101,956	$ 127,481
Deferred setup and organization costs, amortization period	180 months
Theradex Systems, Inc [Member]
Clinical costs charged to operations			$ 1,774,276
Theradex Systems, Inc [Member]
Clinical costs charged to operations	$ 113,551	$ 350,601
Percentage of research and development costs	43.00%	69.00%
Theradex Systems, Inc [Member] \| Phase 1 Clinical [Member]
Total estimated clinical costs to be charged to operations	$ 2,200,000
Percentage of clinical trial service	60.00%
Percentage of clinical center laboratory cost	40.00%
Theradex Systems, Inc [Member]
Advances on research and development contract services, to Theradex	$ 183,063		183,063
Theradex Systems, Inc [Member] \| Phase 1 Clinical [Member]
Advances on research and development contract services, to Theradex to be refunded	$ 181,510		$ 181,510

XML 33 R24.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Anti-dilutive securities excluded from computation of earnings per share	12,325,000	11,941,300
Common Stock Options [Member]
Anti-dilutive securities excluded from computation of earnings per share	7,950,000	6,825,000
Series A Convertible Preferred Stock [Member]
Anti-dilutive securities excluded from computation of earnings per share	4,375,000	2,187,500
Common Stock Warrants [Member]
Anti-dilutive securities excluded from computation of earnings per share		2,928,800

XML 34 R25.htm IDEA: XBRL DOCUMENT

License Agreement (Details Narrative) - USD ($)			3 Months Ended		12 Months Ended
License Agreement (Details Narrative) - USD ($)	Mar. 18, 2016	Dec. 25, 2015	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Licensing fee revenue
License Agreement [Member] \| Taipei Medical University [Member]
Non-refundable milestone payments	$ 200,000	$ 200,000
Licensing fee revenue		$ 200,000
License Agreement [Member] \| Taipei Medical University [Member] \| Cumulative Net Sales [Member]
Royalty percentage		10.00%
License Agreement [Member] \| Taipei Medical University [Member] \| Non-Sale Based Sub-License Income [Member] \| Minimum [Member]
Royalty percentage		10.00%
License Agreement [Member] \| Taipei Medical University [Member] \| Non-Sale Based Sub-License Income [Member] \| Maximum [Member]
Royalty percentage		15.00%
License Agreement [Member] \| Taipei Medical University [Member] \| First Phase 1b/2 Clinical Trial [Member]
Non-refundable milestone payments		$ 50,000
License Agreement [Member] \| Taipei Medical University [Member] \| First Phase 3 Clinical Trial [Member]
Non-refundable milestone payments		150,000
License Agreement [Member] \| Taipei Medical University [Member] \| First Filing of New Drug Application [Member]
Non-refundable milestone payments		$ 200,000

XML 35 R26.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Narrative) - USD ($)							3 Months Ended		12 Months Ended
Stockholders' Equity (Details Narrative) - USD ($)	Mar. 04, 2016	Jan. 28, 2016	Jan. 21, 2016	Mar. 17, 2015	Mar. 06, 2015	Mar. 06, 2015	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Percentage of issued and outstanding shares of common stock held by preferred stock buyer				10.60%
Sale of stock during period, amount				$ 1,750,000
Preferred stock convertible into common stock				2,187,500
Common stock closing price per share				$ 0.25
Legal costs				$ 12,608
Warrants extension average price per share							$ 0.30
Fair value assumptions, expected volatility rate							196.75%	243.00%
Fair value assumptions, expected dividend rate							0.00%	0.00%
Fair value assumptions, risk free interest rate								1.33%
Number of warrants outstanding to purchase of common stock
Chairman and Major Stockholder [Member]
Equity issuance price per share				$ 1.00
Chairman and Major Stockholder [Member]
Common stock closing price per share				$ 0.25
Conversion of advances due to Chairman and major stockholder				$ 92,717
Conversion of advances due to Chairman and major stockholder, shares				92,717
Securities Purchase Agreement [Member]
Sale of preferred stock during period		175,000
Equity issuance price per share		$ 10.00
Sale of stock during period, amount		$ 1,750,000
Proceeds from sale of stock during period, amount	$ 583,333	$ 583,333
Percentage of dividend from annual revenue		1.00%
Preferred stock convertible into common stock		2,187,500
Revenues									$ 200,000
Dividends preferred stock issued and outstanding									$ 2,000
Preferred shares converted to common stock conversion rate		12.5
Minimum [Member]
Fair value assumptions, expected term							2 years 8 months 12 days	3 years 8 months 12 days
Maximum [Member]
Fair value assumptions, expected term							4 years 8 months 12 days	4 years 6 months
Series A Convertible Preferred Stock [Member]
Preferred stock, shares authorized							350,000		175,000
Preferred stock, par value							$ 0.0001		$ 0.0001
Sale of stock during period							175,000
Sale of stock during period, amount							$ 1,750,000
Preferred stock, per share redemption price									$ 50.00
Preferred Stock [Member]
Sale of stock during period			175,000
Equity issuance price per share			$ 0.80
Common stock closing price per share			0.22
Preferred stock, per share redemption price			$ 50.00
Warrant Eight [Member]
Outstanding warrants to acquire shares of common stock extended					2,928,800
Warrants acquisition expiration date					Mar. 31, 2015
Warrants Extensions Four [Member]
Fair value of warrants extension amount						$ 34,016
Warrants extension average price per share					$ 0.01	$ 0.01
Fair value assumption stock price					0.30	$ 0.30
Fair value assumptions, expected volatility rate						199.00%
Fair value assumptions, expected dividend rate						0.00%
Fair value assumptions, risk free interest rate						0.01%
Warrants Extensions Four [Member] \| Minimum [Member]
Fair value assumptions, exercise price					$ 0.50	$ 0.50
Fair value assumptions, expected term					25 days
Warrants Extensions Four [Member] \| Maximum [Member]
Fair value assumptions, exercise price					$ 0.75	$ 0.75
Fair value assumptions, expected term						40 days
Warrants Extensions Four [Member] \| Warrants 0.50 Price Per Share [Member]
Common stock exercisable price per share					$ 0.50	$ 0.50
Warrants outstanding					1,853,800	1,853,800
Warrants Extensions Four [Member] \| Warrants 0.75 Price Per Share [Member]
Common stock exercisable price per share					$ 0.75	$ 0.75
Warrants outstanding					1,075,000	1,075,000
Warrants Extensions Five [Member]
Fair value of warrants extension amount						$ 171,757
Warrants extension average price per share					$ 0.06	$ 0.06
Fair value assumption stock price					0.30	$ 0.30
Fair value assumptions, expected term						15 days
Fair value assumptions, expected volatility rate						199.00%
Fair value assumptions, expected dividend rate						0.00%
Fair value assumptions, risk free interest rate						0.01%
Warrants Extensions Five [Member] \| Minimum One [Member]
Fair value assumptions, exercise price					0.50	$ 0.50
Warrants Extensions Five [Member] \| Maximum One [Member]
Fair value assumptions, exercise price					0.75	0.75
Warrants Extensions Five [Member] \| Minimum Two [Member]
Fair value assumptions, exercise price					0.25	0.25
Warrants Extensions Five [Member] \| Maximum Two [Member]
Fair value assumptions, exercise price					0.375	0.375
Warrants Extensions Six [Member]
Warrants extension average price per share					$ 0.30	0.30
Outstanding warrants to acquire shares of common stock exercised					1,050,000
Proceeds from exercise of warrants					$ 315,000
Warrants Extensions Six [Member] \| Dr. Debbie Schwartzberg [Member]
Outstanding warrants to acquire shares of common stock					500,000
Warrants Extensions Six [Member] \| Philip F. Palmedo [Member]
Outstanding warrants to acquire shares of common stock					300,000
Warrants Extensions Six [Member] \| Minimum [Member]
Common stock exercisable price per share					$ 0.25	0.25
Warrants Extensions Six [Member] \| Maximum [Member]
Common stock exercisable price per share					$ 0.375	$ 0.375
January 28, 2016 [Member] \| Series A Convertible Preferred Stock [Member] \| Minimum [Member]
Preferred stock, shares authorized							175,000
January 28, 2016 [Member] \| Series A Convertible Preferred Stock [Member] \| Maximum [Member]
Preferred stock, shares authorized							350,000
June 3, 2016 [Member] \| Securities Purchase Agreement [Member]
Proceeds from sale of stock during period, amount							$ 583,334
Preferred Stock [Member]
Preferred stock, shares authorized							10,000,000
Preferred stock, par value							$ 0.001
Number of designated preferred stock, shares							175,000
Undesignated preferred stock, shares							9,650,000
Non-Voting Series A Convertible Preferred Stock [Member'
Sale of stock during period				175,000
Equity issuance price per share				$ 10.00
Sale of stock during period, amount				$ 1,750,000

XML 36 R27.htm IDEA: XBRL DOCUMENT

Money Market Funds (Details Narrative) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Money market funds	$ 870,773	$ 104,095

XML 37 R28.htm IDEA: XBRL DOCUMENT

Money Market Funds - Fair Value Assets Measured on Recurring Basis (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Money market funds	$ 870,773	$ 104,095
Money Market Funds [Member]
Money market funds	870,773	104,095
Level 1 [Member] \| Money Market Funds [Member]
Money market funds	$ 870,773	$ 104,095
Level 2 [Member] \| Money Market Funds [Member]
Money market funds
Level 3 [Member] \| Money Market Funds [Member]
Money market funds

XML 38 R29.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)		3 Months Ended		12 Months Ended
	Mar. 17, 2015	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2014
Common stock, closing price per share	$ 0.25
Consulting and advisory fees		$ 6,250	$ 6,250
Stock based compensation expense relating to directors officers and other related parties		0	74,901
Eric Forman [Member]
Legal and consulting fees charged to operations for services rendered by Eric Foreman		12,000	12,000
Dr Kathleen P Mullinix [Member]
Annual cash compensation				$ 25,000
Consulting and advisory fees				25,000
Dr. Kovach [Member]
Due to stockholder				$ 92,717
Related parties advance converted into common stock, shares	92,717
Common stock, effective price per share	$ 1.00
Common stock, closing price per share	$ 0.25
Salaries paid		$ 15,000	$ 15,000

XML 39 R30.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Details Narrative) - USD ($)							3 Months Ended			12 Months Ended
Stock-Based Compensation (Details Narrative) - USD ($)	Nov. 28, 2015	Sep. 14, 2015	Oct. 07, 2014	Jan. 28, 2014	Dec. 24, 2013	Jun. 20, 2007	Mar. 31, 2016	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2015	Oct. 07, 2015	Jun. 24, 2015	Apr. 07, 2015	Jan. 28, 2015	Dec. 31, 2014	Jun. 24, 2014
Options exercisable period							2 years 4 months 24 days
Options, exercisable price per share							$ 0.586			$ 0.586
Options, fair value							$ (30,370)
Fair value of warrants									$ 34,016
Fair market value, per share							$ 0.12			$ 0.296
Stock based compensation							$ (30,370)		83,994
Total deferred compensation expense for outstanding value of unvested stock options							$ 74,000
Intrinsic value of exercisable but unexercised in-the-money stock options									31,300
Outstanding options to acquire common stock non-vested							1,150,000
Agreemnt With ProActive Capital Resources Group LLC [Member]
Stock options granted to purchase common stock			250,000
Number of stock options available for issuance			125,000
Options exercisable period			1 year
Options, exercisable price per share			$ 0.25
Options vest			125,000										125,000		125,000
Stock price per share			$ 0.066
Services cost			$ 1,500
Fair value of warrants			$ 33,000
Issuance of warrants to purchase of common stock			500,000
Operations for the aggregate fair value of these securities								$ 76,750
Dr. Kathleen P. Mullinix [Member]
Fair value of common stock grants									12,500
Advisory Agreement With Dr. Fritz Henn [Member]
Stock options granted to purchase common stock	200,000
Options exercisable period	5 years
Options, exercisable price per share	$ 0.50
Options vest	100,000
Stock price per share	$ 0.5168
Charges to operations							$ 1,159
Options, vesting date	Nov. 28, 2016
Fair value of warrants	$ 103,360
Number of option fully vested	51,680
Advisory Agreement With Dr. Fritz Henn [Member] \| November 28, 2016 [Member]
Options vest	100,000
Consulting Arrangements [Member] \| Mr.Schwartzberg [Member]
Charges to operations									74,901
Consulting Arrangements [Member] \| Mr.Schwartzberg [Member]
Stock options granted to purchase common stock				4,000,000
Options exercisable period				5 years
Options, exercisable price per share				$ 0.50
Options vest				2,000,000										2,000,000
Options, fair value				$ 596,400
Stock price per share				$ 0.15
Charges to operations				$ 298,200
Options, vesting date				Jan. 28, 2015
NDA Agreement [Member]
Stock options granted to purchase common stock					100,000
Options exercisable period					5 years
Options, exercisable price per share					$ 0.13
Options vest												25,000				25,000
Options, fair value					$ 12,960
Stock price per share					$ 0.13
Charges to operations							(10,796)		2,316
Advisory Agreement [Member]
Charges to operations							$ 6,777		$ 6,777
Advisory Agreement [Member] \| Andrew Robell [Member]
Options, exercisable price per share			$ 0.50
Options vest			100,000								100,000
Stock price per share			$ 0.10
2007 Stock Compensation Plan [Member]
Number of restricted stock issued						2,500,000
Stock options granted to purchase common stock							550,000
Number of stock options available for issuance							1,950,000
Vesting On June 24, 2016 [Member] \| NDA Agreement [Member]
Options vest					25,000
Vesting On June 24, 2017 [Member] \| NDA Agreement [Member]
Options vest					25,000
Andrew Robell [Member] \| Advisory Agreement [Member]
Stock options granted to purchase common stock			200,000
Options exercisable period			5 years
Options, fair value			$ 20,000
Vested [Member] \| Advisory Agreement [Member] \| Andrew Robell [Member]
Options, fair value			$ 10,000
Collaboration Agreement Bio PharmaWorks LLC [Member]
Stock options granted to purchase common stock		1,000,000
Options exercisable period		5 years
Options, exercisable price per share		$ 0.26
Options, fair value		$ 260,000
Charges to operations							$ (20,733)
Issuance of warrants to purchase of common stock		1,000,000
Collaboration Agreement Bio PharmaWorks LLC [Member] \| First Warrant [Member] \| September 14, 2016 [Member]
Options exercisable period							5 years
Stock price per share							$ 0.2568
Fair value of warrants							$ 128,400
Issuance of warrants to purchase of common stock							500,000
Fair market value, per share							$ 1.00
Collaboration Agreement Bio PharmaWorks LLC [Member] \| Second Warrant [Member] \| September 14, 2017 [Member]
Options exercisable period							5 years
Stock price per share							$ 0.2557
Fair value of warrants							$ 127,850
Issuance of warrants to purchase of common stock							500,000
Fair market value, per share							$ 2.00

XML 40 R31.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Fair Value of each Option Award Estimated Assumption (Details)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Risk-free interest rate, minimum	0.74%
Risk-free interest rate, maximum	1.23%
Risk-free interest rate		1.33%
Expected dividend yield	0.00%	0.00%
Expected volatility	196.75%	243.00%
Minimum [Member]
Expected life	2 years 8 months 12 days	3 years 8 months 12 days
Maximum [Member]
Expected life	4 years 8 months 12 days	4 years 6 months

XML 41 R32.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of Stock Option Activity (Details)	3 Months Ended
	Mar. 31, 2016 $ / shares shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of shares, options outstanding, at the beginning \| shares	7,950,000
Number of shares, granted \| shares
Number of shares, exercised \| shares
Number of shares, expired \| shares
Number of shares, options outstanding, at the end \| shares	7,950,000
Number of shares, options exercisable, at the beginning \| shares	6,800,000
Number of shares, options exercisable, at the end \| shares	6,800,000
Weighted average exercise price, options outstanding, at the beginning \| $ / shares	$ 0.697
Weighted average exercise price, granted \| $ / shares
Weighted average exercise price, exercised \| $ / shares
Weighted average exercise price, expired \| $ / shares
Weighted average exercise price, options outstanding, at the end \| $ / shares	$ 0.697
Weighted average exercise price, options exercisable, at the beginning \| $ / shares	0.586
Weighted average exercise price, options exercisable, at the end \| $ / shares	$ 0.586
Weighted average remaining contractual life (in years), options outstanding	2 years 8 months 9 days
Weighted average remaining contractual life (in years), options exercisable	2 years 4 months 24 days

XML 42 R33.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Exercise Prices of Common Stock Options Outstanding and Exercisable (Details) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Exercise Prices	$ 0.697	$ 0.697
Options Outstanding (Shares)	7,950,000
Options Exercisable (Shares)	6,800,000
Exercise Price Three [Member]
Exercise Prices	$ .500
Options Outstanding (Shares)	4,400,000
Options Exercisable (Shares)	4,300,000
Exercise Price Four [Member]
Exercise Prices	$ .650
Options Outstanding (Shares)	700,000
Options Exercisable (Shares)	700,000
Exercise Price Five [Member]
Exercise Prices	$ .980
Options Outstanding (Shares)	250,000
Options Exercisable (Shares)	250,000
Exercise Price Six [Member]
Exercise Prices	$ 1.000
Options Outstanding (Shares)	1,500,000
Options Exercisable (Shares)	1,000,000
Exercise Price Seven [Member]
Exercise Prices	$ 2.000
Options Outstanding (Shares)	500,000
Options Exercisable (Shares)
Exercise Price One [Member]
Exercise Prices	$ 0.130
Options Outstanding (Shares)	100,000
Options Exercisable (Shares)	50,000
Exercise Price Two [Member]
Exercise Prices	$ 0.250
Options Outstanding (Shares)	500,000
Options Exercisable (Shares)	500,000

XML 43 R34.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative) - USD ($)			3 Months Ended		8 Months Ended	12 Months Ended	39 Months Ended
	Oct. 07, 2014	Dec. 24, 2013	Mar. 31, 2016	Mar. 31, 2015	Sep. 14, 2015	Dec. 31, 2014	Mar. 31, 2016
Consulting and advisory fees			$ 6,250	$ 6,250
Aggregate principal cash obligation and commitments amount			494,914				$ 494,914
Principal cash obligations and commitments included in current liabilities			75,259				75,259
Collaboration Agreement Bio PharmaWorks LLC [Member]
Consulting and advisory fees			30,000
Charges to operations			30,000
Dr. Kathleen P. Mullinix [Member]
Consulting and advisory fees			6,250	6,250
Agreemnt With ProActive Capital Resources Group LLC [Member]
Consulting and advisory fees	$ 1,500
Charges to operations			4,500
Dr Kathleen P Mullinix [Member]
Consulting and advisory fees						$ 25,000
Annual cash compensation						$ 25,000
Collaboration Agreement Bio PharmaWorks LLC [Member]
Consulting and advisory fees					$ 10,000
Theradex Systems, Inc [Member]
Clinical costs charged to operations							$ 1,774,276
Theradex Systems, Inc [Member]
Clinical costs charged to operations			113,551	350,601
Theradex Systems, Inc [Member] \| Phase 1 Clinical [Member]
Estimated total clinical costs to be charged to operations			$ 2,200,000
Percentage of clinical trial service			60.00%
Percentage of clinical center laboratory cost			40.00%
NDA Consulting Corp [Member]
Consulting and advisory fees		$ 4,000	$ 4,000	$ 4,000

XML 44 R35.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Schedule of Principal Cash Obligations and Commitments (Details)	Mar. 31, 2016 USD ($)
Research and development contracts	$ 41,004
Clinical trial agreements	256,910
Consulting agreements	197,000
Total	494,914
Payments Due By 2016 [Member]
Research and development contracts	41,004
Clinical trial agreements	256,910
Consulting agreements	107,000
Total	$ 404,914
Payments Due By 2017 [Member]
Research and development contracts
Clinical trial agreements
Consulting agreements	$ 90,000
Total	$ 90,000
Payments Due By 2018 [Member]
Research and development contracts
Clinical trial agreements
Consulting agreements
Total
Payments Due By 2019 [Member]
Research and development contracts
Clinical trial agreements
Consulting agreements
Total
Payments Due By 2020 [Member]
Research and development contracts
Clinical trial agreements
Consulting agreements
Total

EXCEL 45 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 49 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 156 205 1 false 82 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://lixte.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://lixte.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://lixte.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://lixte.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) Sheet http://lixte.com/role/StatementsOfOperationsParenthetical Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statement of Stockholders’ Equity (Unaudited) Sheet http://lixte.com/role/StatementOfStockholdersEquity Condensed Consolidated Statement of Stockholders’ Equity (Unaudited) Statements 6 false false R7.htm 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://lixte.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - Organization, Business and Basis of Presentation Sheet http://lixte.com/role/OrganizationBusinessAndBasisOfPresentation Organization, Business and Basis of Presentation Notes 8 false false R9.htm 00000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://lixte.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - License Agreement Sheet http://lixte.com/role/LicenseAgreement License Agreement Notes 10 false false R11.htm 00000011 - Disclosure - Stockholders' Equity Sheet http://lixte.com/role/StockholdersEquity Stockholders' Equity Notes 11 false false R12.htm 00000012 - Disclosure - Money Market Funds Sheet http://lixte.com/role/MoneyMarketFunds Money Market Funds Notes 12 false false R13.htm 00000013 - Disclosure - Related Party Transactions Sheet http://lixte.com/role/RelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 00000014 - Disclosure - Stock-Based Compensation Sheet http://lixte.com/role/Stock-basedCompensation Stock-Based Compensation Notes 14 false false R15.htm 00000015 - Disclosure - Commitments and Contingencies Sheet http://lixte.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 00000016 - Disclosure - Subsequent Events Sheet http://lixte.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 00000017 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://lixte.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://lixte.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://lixte.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - Money Market Funds (Tables) Sheet http://lixte.com/role/MoneyMarketFundsTables Money Market Funds (Tables) Tables http://lixte.com/role/MoneyMarketFunds 19 false false R20.htm 00000020 - Disclosure - Stock-Based Compensation (Tables) Sheet http://lixte.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://lixte.com/role/Stock-basedCompensation 20 false false R21.htm 00000021 - Disclosure - Commitments and Contingencies (Tables) Sheet http://lixte.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://lixte.com/role/CommitmentsAndContingencies 21 false false R22.htm 00000022 - Disclosure - Organization, Business and Basis of Presentation (Details Narrative) Sheet http://lixte.com/role/OrganizationBusinessAndBasisOfPresentationDetailsNarrative Organization, Business and Basis of Presentation (Details Narrative) Details http://lixte.com/role/OrganizationBusinessAndBasisOfPresentation 22 false false R23.htm 00000023 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://lixte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://lixte.com/role/SummaryOfSignificantAccountingPoliciesTables 23 false false R24.htm 00000024 - Disclosure - Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://lixte.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 24 false false R25.htm 00000025 - Disclosure - License Agreement (Details Narrative) Sheet http://lixte.com/role/LicenseAgreementDetailsNarrative License Agreement (Details Narrative) Details http://lixte.com/role/LicenseAgreement 25 false false R26.htm 00000026 - Disclosure - Stockholders' Equity (Details Narrative) Sheet http://lixte.com/role/StockholdersEquityDetailsNarrative Stockholders' Equity (Details Narrative) Details http://lixte.com/role/StockholdersEquity 26 false false R27.htm 00000027 - Disclosure - Money Market Funds (Details Narrative) Sheet http://lixte.com/role/MoneyMarketFundsDetailsNarrative Money Market Funds (Details Narrative) Details http://lixte.com/role/MoneyMarketFundsTables 27 false false R28.htm 00000028 - Disclosure - Money Market Funds - Fair Value Assets Measured on Recurring Basis (Details) Sheet http://lixte.com/role/MoneyMarketFunds-FairValueAssetsMeasuredOnRecurringBasisDetails Money Market Funds - Fair Value Assets Measured on Recurring Basis (Details) Details 28 false false R29.htm 00000029 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://lixte.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://lixte.com/role/RelatedPartyTransactions 29 false false R30.htm 00000030 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://lixte.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://lixte.com/role/Stock-basedCompensationTables 30 false false R31.htm 00000031 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of each Option Award Estimated Assumption (Details) Sheet http://lixte.com/role/Stock-basedCompensation-ScheduleOfFairValueOfEachOptionAwardEstimatedAssumptionDetails Stock-Based Compensation - Schedule of Fair Value of each Option Award Estimated Assumption (Details) Details 31 false false R32.htm 00000032 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) Sheet http://lixte.com/role/Stock-basedCompensation-SummaryOfStockOptionActivityDetails Stock-Based Compensation - Summary of Stock Option Activity (Details) Details 32 false false R33.htm 00000033 - Disclosure - Stock-Based Compensation - Exercise Prices of Common Stock Options Outstanding and Exercisable (Details) Sheet http://lixte.com/role/Stock-basedCompensation-ExercisePricesOfCommonStockOptionsOutstandingAndExercisableDetails Stock-Based Compensation - Exercise Prices of Common Stock Options Outstanding and Exercisable (Details) Details 33 false false R34.htm 00000034 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://lixte.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://lixte.com/role/CommitmentsAndContingenciesTables 34 false false R35.htm 00000035 - Disclosure - Commitments and Contingencies - Schedule of Principal Cash Obligations and Commitments (Details) Sheet http://lixte.com/role/CommitmentsAndContingencies-ScheduleOfPrincipalCashObligationsAndCommitmentsDetails Commitments and Contingencies - Schedule of Principal Cash Obligations and Commitments (Details) Details 35 false false All Reports Book All Reports lixt-20160331.xml lixt-20160331.xsd lixt-20160331_cal.xml lixt-20160331_def.xml lixt-20160331_lab.xml lixt-20160331_pre.xml true true ZIP 51 0001493152-16-009470-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-16-009470-xbrl.zip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end